(RESN) To Present November 19 at the Southwest IDEAS Investor Conference

Presentation and Webcast at 2:30 p.m. CT

Resonant Inc. (NASDAQ: RESN), a late-stage development company creating innovative filter designs for radio frequency, or RF, front-ends for the mobile device industry, today announced that Mr. Terry Lingren, Chairman and CEO and John Philpott, CFO, will present at the Southwest IDEAS Conference on Wednesday, November 19, 2014. The conference is being held at the Marriott – Quorum Hotel in Addison, Texas.

The Company’s presentation is scheduled to begin at 2:30 p.m. CT. A live and archived webcast of the presentation can be accessed at http://www.wsw.com/webcast/threepa15/resn or at the Company’s website: http://resonant.com.

About IDEAS Investor Conferences

The mission of the IDEAS Conferences is to provide independent regional venues for quality companies to present their investment merits to an influential audience of investment professionals. IDEAS Investor Conferences are “Sponsored BY the Buyside FOR the Buyside” and benefit the regional investment communities. Conference sponsors collectively have more than $200 Billion in assets under management. The IDEAS Investor Conferences are held annually in Boston, Chicago and Dallas and are produced by Three Part Advisors, LLC. Additional information about the events can be located at www.IDEASconferences.com.

About Resonant Inc.

Resonant is creating innovative filter designs for radio frequency, or RF, front-ends for the mobile device industry. The RF front-end is the circuitry in a mobile device responsible for analog signal processing and is located between the device’s antenna and its digital baseband. The Company uses a fundamentally new technology called Infinite Synthesized Networks®, or ISN®, to configure and connect resonators, the building blocks of RF filters. Filters are a critical component of the RF front-end used to select desired radio frequency signals and reject unwanted signals. Resonant plans to use ISN to develop new classes of filter designs. For information, please visit www.resonant.com.

Safe Harbor for Forward-Looking Statements

This presentation may contain forward-looking statements. Forward-looking statements include the following subjects, among others: the status of filter designs under development, the prospects for licensing filter designs upon completion of development, plans for other filter designs not currently in development, potential customers for our designs, the timing and amount of future royalty streams, the expected duration of our capital resources, our hiring plans, our cash flow forecast, the impact of our designs on the mobile device market, and our business strategy. Forward-looking statements are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: our limited operating history (particularly as a new public company); management of R&D efforts; the acceptance of our filter designs by potential customers; the ability of our customers (or their manufacturers) to fabricate our designs in commercial quantities; the risk that the intense competition and rapid technological change in our industry renders our designs less useful or obsolete; our ability to find, recruit and retain the highly skilled personnel required for our design process in sufficient numbers to support our growth; our ability to manage growth; and general market, economic and business conditions. Additional factors that could cause actual results to differ materially from those anticipated by our forward-looking statements are under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent Quarterly Report (Form 10-Q), filed with the Securities and Exchange Commission. Forward-looking statements are made as of the date of this release, and we expressly disclaim any obligation or undertaking to update forward-looking statements.

(NETE) CEO Oleg Firer on Q3 2014 Results – Earnings Call Transcript

Nov. 17, 2014 9:04 PM –

Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Net Element 2014 Third Quarter Financial Results and Business Update Conference Call. During today’s presentation, all parties will be in a listen-only mode. [Operator Instructions] I would like to remind listeners that during the call management’s prepared remarks may contain forward looking statements which are subject to risks and uncertainties. Management may make additional forward looking statements in response to your questions today. Therefore the company claims protection under Safe Harbor for forward looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from the results discussed today and therefore we refer you to more detailed discussion of these risks and uncertainties in the company’s filing with the SEC. Any projections as to the company’s future performance represented by management include estimates today as of November 17, 2014 and the company no assumes no obligation to update these projections in the future as market conditions change. The recording and certain financial information provided during the call is available at www.netelement.com on the Investor Relations page.

At this time, I’d like to turn the call over to Oleg Firer, CEO. Oleg, please be go ahead.

Oleg Firer

Thank you and thanks to everyone who has joined our call today. We are here today to discuss the results from the third quarter of 2014 and then give an opportunity for those of you listening in to ask questions during the Q&A session. I’d like to begin today’s conference call by acknowledging the highlights from the third quarter of 2014.

Our revenues for the quarter were $6,026,961 versus $4,912,035 for the quarter ended June 30, 2014, a quarter-over-quarter increase of 23%. Operating activities provided $2,959,201 of positive cash flow for the period contrasted with $6,366,221 of net cash used in the third quarter of 2013. In September, we have announced $11 million financing from Alfa-Bank. The financing will allow Net Element to accelerate its growth efforts in Russia. In September, we have finalized debt exchange transaction with Crede Capital. As part of this transaction we have eliminated more than $15 million of debt from our [balance] [ph] sheet. This financial transaction settles most of the company’s debt obligations.

In September, we have also announced availability of Apple Pay to merchants through Unified Payments offering. Currently point of sales terminals deployed by the company are NFC and EMV enabled offering merchants an ability to accept Apple Pay and EMV transactions to the point of sale.

In July, we have appointed financial services industry veteran William Healy to Net Element’s Board of Directors. In July, we have also announced $10 million financing from RBL Capital Group. This financing will allow Net Element to accelerate its growth initiatives.

We are pleased with our third quarter performance which include significant debt reduction and narrowed quarterly loss. In Russia, we have successfully restructured the business and are confident in a significant quarter-over-quarter growth an ongoing basis.

Pivoting from a strong balance sheet, our activities and improvement have set the pace for continued growth and demonstrate our commitment to increasing company value. Third quarter of 2014 was very busy quarter for us which I believe had positive impact on both operations and financials of the company. And we are well positioned to continue to growth trend for the remainder of 2014 and into 2015.

Now I’d like to introduce Jonathan New, Net Element’s Chief Financial Officer, who will provide comment on our financials. Jon, please proceed.

Jonathan New

Thank you, Oleg. Good afternoon, everybody. I’ll provide some brief highlights for the quarter, but please also refer to the 10-Q that was filed last week with the SEC for full details.

(ARIS) Briggs & Stratton Corporation Selects ARI’s PartStream®

MILWAUKEE, Nov. 18, 2014  — ARI Network Services, Inc. (Nasdaq:ARIS) announced today that Briggs & Stratton Corporation has launched ARI’s PartStream® illustrated parts lookup on its consumer-facing website at BriggsandStratton.com.

“We strive to continue to improve the user experience on our website. We actively solicit and review user feedback and in doing so, uncovered that our parts lookup could use improvement,” said Dave Cluka, Director of Customer Experience at Briggs & Stratton. “We believe that PartStream can not only provide a better user experience, but also reduce the burden on our team to maintain the previous, custom-built parts lookup tool.”

The launch of PartStream builds upon a 15-year relationship with the manufacturer. Briggs & Stratton also uses ARI’s B2B electronic parts lookup application, PartSmart Web®, as well as ARI’s data publishing tool, PartSmart Data Manager®. In addition, ARI provides Briggs & Stratton’s dealer network with access to parts catalogs for the manufacturer’s complete brand portfolio through PartSmart®, ARI’s award-winning electronic parts lookup tool.

“We welcome the opportunity to extend our relationship with Briggs & Stratton to provide consumers with a better online parts lookup experience,” said Roy W. Olivier, President and CEO of ARI. “Identifying and ordering the right part online can be frustrating, even for the most technically-savvy consumer. We’re confident that PartStream will reduce frustration, improve customer satisfaction and drive more online parts sales.”

PartStream, ARI’s illustrated parts lookup solution, can easily be added to any existing website to fuel eCommerce sales. Part numbers and descriptions are automatically indexed for search engine optimization, making it easy for buyers to find and purchase parts online.

About Briggs & Stratton Corporation

Briggs & Stratton Corporation, headquartered in Milwaukee, Wisconsin, is the world’s largest producer of gasoline engines for outdoor power equipment. Its wholly owned subsidiaries include North America’s number one marketer of portable generators and pressure washers, and it is a leading designer, manufacturer and marketer of lawn and garden, turf care and job site products through its Simplicity®, Snapper®, Ferris®, Murray®, Allmand, Branco® and Victa® brands. Briggs & Stratton products are designed, manufactured, marketed and serviced in over 100 countries on six continents.

About ARI

ARI Network Services, Inc. (ARI) (Nasdaq:ARIS) offers an award-winning suite of data-driven software tools and marketing services to help dealers, equipment manufacturers and distributors in selected vertical markets Sell More Stuff!™ – online and in-store. Our innovative products are powered by a proprietary data repository of enriched original equipment and aftermarket electronic content spanning more than 10.5 million active part and accessory SKUs, 469,000 models and $1.7 billion in retail product value. Business is complicated, but we believe our customers’ technology tools don’t have to be. We remove the complexity of selling and servicing new and used vehicle inventory, parts, garments and accessories (PG&A) for customers in the automotive tire and wheel aftermarket, powersports, outdoor power equipment, marine, home medical equipment, recreational vehicles and appliance industries. More than 22,000 equipment dealers, 195 distributors and 1,500 manufacturers worldwide leverage our web and eCatalog platforms to Sell More Stuff!™ For more information on ARI, visit investor.arinet.com.

Additional Information

• Follow @ARI_Net on Twitter: twitter.com/ARI_Net
• Become a fan of ARI on Facebook: www.facebook.com/ARInetwork
• Join us on G+: plus.google.com
• LinkedIn: www.linkedin.com
• Read more about ARI: investor.arinet.com/about-us

CONTACT: For media inquiries, contact:
         Colleen Brousil, Director of Marketing, ARI
         +1-414-973-4323, colleen.brousil@arinet.com

         Investor inquiries, contact:
         Steven Hooser, Three Part Advisors
         +1.214.872.2710, shooser@threepa.com

(ARAY) First CyberKnife® Full-Body Radiosurgery System in Manhattan Now Treating Patients

SUNNYVALE, Calif., Nov. 18, 2014  — Accuray Incorporated (Nasdaq: ARAY) announced today that the first CyberKnife^® System in Manhattan is now treating patients at Winthrop University Hospital’s NYCyberKnife Center. Winthrop’s decision to install the latest generation CyberKnife M6™ System reinforces its growing reputation as a dedicated radiosurgery device that delivers extremely precise full-body treatments while maximizing patients’ quality of life during and after treatment.

The CyberKnife M6 System’s true robotic mobility enables it to deliver radiation beams from a wide range of angles around the body, precisely targeting tumors while avoiding healthy tissue. It can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney. The treatment – which delivers high doses of radiation to tumors with extreme accuracy – may offer hope to patients who have inoperable or surgically complex tumors, or who may prefer a clinically effective, non-surgical option.

The CyberKnife System’s ability to automatically stay on target despite patient and tumor motion is what truly differentiates it from other forms of radiation therapy systems. It automatically follows the tumor throughout the treatment process, intelligently delivering radiation with sub-millimeter precision. This unique, dynamic motion compensation feature enables clinicians to precisely maximize dose, minimize side effects and maximize patient comfort.

Quotes
Joshua H. Levine, president and chief executive officer of Accuray: “The CyberKnife System is a transformative innovation, changing the face of cancer treatment and enabling clinicians to help their patients live longer, better lives. We’re honored that Winthrop selected our system and want to congratulate the team as they expand their significant clinical expertise to treating patients in Manhattan with the CyberKnife System.”

Jonathan Haas, MD, chief, Division of Radiation Oncology at Winthrop-University Hospital: “The Winthrop team is excited to be the first center in Manhattan to offer patients requiring radiation therapy the option to receive treatment with the CyberKnife System. We saw the considerable benefits the system has provided to our patients in Mineola, so when considering alternatives for our new location, it was an easy choice. We selected the CyberKnife M6 System because it includes the features and precision of the previous model, with the potential to provide faster treatment times and expand access to more patients.”

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops,
manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to adoption and acceptance of the company’s products, clinical experience, clinical applications, clinical results, patient outcomes and Accuray’s leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading “Risk Factors” in the company’s report on Form 10-K, filed on August 29, 2014, the company’s report on Form 10-Q, filed on November 7, 2014, and the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Video – http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/ENR/The-CyberKnife(R)-System-Animation-10-9-14.mp4

(PLUG) Moves Into Ground Support Equipment Market

GenFuel Infrastructure to Support Tuggers at Memphis Airport

LATHAM, N.Y., Nov. 18, 2014  — Plug Power Inc. (Nasdaq:PLUG), a leader in providing clean, reliable energy products, has successfully completed installation of its first GenFuel hydrogen infrastructure for the ground support equipment (GSE) market at the Memphis Airport.

This GenFuel infrastructure deployment includes a standard hydrogen storage tank, compression system, fuel pipelines, and Plug Power’s first outdoor GenFuel hydrogen dispensers that will be used for a 15-truck fleet of airport tuggers powered by Plug Power fuel cells.

The outdoor hydrogen dispenser varies from its indoor counterpart by providing an all-weather enclosure capable of protecting the equipment from harsh elements that can be experienced on an airport tarmac such as rain, snow, direct sun, high winds and extreme temperatures.

Similar to the GenFuel experience at other customer sites, the Memphis truck drivers will simply pull their GSE vehicles up to the dispenser and personally refuel in just three to four minutes.

“Plug Power’s ability to offer customers both indoor and outdoor GenFuel solutions allows us to broaden our reach even further into adjacent markets like ground support equipment,” said Andy Marsh, CEO at Plug Power. “The all-weather outdoor dispenser is a natural addition to the GenFuel portfolio.”

The Plug Power GSE fuel cells are specially designed to power airport tuggers, and are based on proven GenDrive architecture. But, the rugged GSE units differ from GenDrive units sold for the material handling market, due in part to the larger 20kW power output requirements, and because this application is extremely demanding, requiring units to be run and stored exclusively outdoors. Despite the harsh conditions, the fuel cells operate at least twice as efficiently as diesel engines, providing customers with a positive economic payback based on fuel savings.

Hydrogen fuel cells generate only heat and water as waste byproducts. Using fuel cells as the power source, the tugger immediately becomes a zero emission vehicle. Upon start-up, the fuel cell-powered vehicle becomes compliant with EPA Tier 4 final emissions standards.

The outdoor fueling infrastructure opens the door for Plug Power to provide hydrogen fueling to other new applications, such as electric vehicle range extenders.

About Plug Power Inc.

The architects of modern fuel cell technology, Plug Power is revolutionizing the industry with cost-effective power solutions that increase productivity, lower operating costs and reduce carbon footprints. Long-standing relationships with industry leaders, including Walmart, Sysco, Procter & Gamble, and Mercedes Benz, forged the path for Plug Power’s innovative GenKey hydrogen and fuel cell system solutions. With more than 6,000 GenDrive units shipped to material handling customers, accumulating over 20 million hours of runtime, Plug Power manufactures tomorrow’s incumbent power solutions today. Additional information about Plug Power is available at www.plugpower.com.

Safe Harbor Statement

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. (“PLUG”), including but not limited to statements about PLUG’s forecast of financial performance, order bookings, business model, strategy and growth opportunities. You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, the risk that we continue to incur losses and might never achieve or maintain profitability; the risk that we will need to raise additional capital to fund our operations and such capital may not be available to us; the risk that our lack of extensive experience in manufacturing and marketing products may impact our ability to manufacture and market products on a profitable and large-scale commercial basis; the risk that unit orders will not ship, be installed and/or converted to revenue, in whole or in part; the risk that pending orders may not convert to purchase orders, in whole or in part; the risk that a loss of one or more of our major customers could result in a material adverse effect on our financial condition; the risk that a sale of a significant number of shares of stock could depress the market price of our common stock; the risk that negative publicity related to our business or stock could result in a negative impact on our stock value and profitability; the risk of potential losses related to any product liability claims or contract disputes; the risk of loss related to an inability to maintain an effective system of internal controls or key personnel; the risks related to use of flammable fuels in our products; the cost and timing of developing, marketing and selling our products and our ability to raise the necessary capital to fund such costs; the ability to achieve the forecasted gross margin on the sale of our products; the risk that our actual net cash used for operating expenses may exceed the projected net cash for operating expenses; the cost and availability of fuel and fueling infrastructures for our products; market acceptance of our products, including GenDrive and GenKey systems; the volatility of our stock price; our ability to establish and maintain relationships with third parties with respect to product development, manufacturing, distribution and servicing and the supply of key product components; the cost and availability of components and parts for our products; our ability to develop commercially viable products; our ability to reduce product and manufacturing costs; our ability to successfully expand our product lines; our ability to successfully expand internationally; our ability to improve system reliability for our GenDrive and GenKey systems; competitive factors, such as price competition and competition from other traditional and alternative energy companies; our ability to protect our intellectual property; the cost of complying with current and future federal, state and international governmental regulations; risks associated with potential future acquisitions; and other risks and uncertainties referenced in our public filings with the Securities and Exchange Commission. For additional disclosure regarding these and other risks faced by PLUG, see disclosures contained in PLUG’s public filings with the Securities and Exchange Commission (the “SEC”) including, the “Risk Factors” section of PLUG’s Annual Report on Form 10-K for the year ended December 31, 2013. You should consider these factors in evaluating the forward-looking statements included in this presentation and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and PLUG undertakes no obligation to update such statements as a result of new information.

CONTACT: Media Contact:
         Teal Vivacqua
         Plug Power Inc.
         Phone: (518) 782-7700 ext. 1269
         media@plugpower.com

(ONVO) Announces Commercial Release of the exVive3D™ Human Liver Tissue

SAN DIEGO, Nov. 18, 2014  — Organovo Holdings, Inc. (NYSE MKT: ONVO) (“Organovo”), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced the full commercial release of the exVive3D^TM Human Liver Tissue for preclinical drug discovery testing.  Initially, clients will be able to access the technology through Organovo’s contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.

Organovo’s exVive3D Liver Models are bioprinted, living 3D human liver tissues consisting of primary human hepatocytes, stellate, and endothelial cell types, which are found in native human liver. The exVive3D Liver Models are created using Organovo’s proprietary 3D bioprinting technology that builds functional living tissues containing precise and reproducible architecture. The tissues are functional and stable for at least 42 days, which enables assessment of drug effects over study durations that well beyond those offered by industry-standard 2D liver cell culture systems.

Organovo has previously shown that exVive3D Liver Models produce important liver proteins including albumin, fibrinogen and transferrin, synthesize cholesterol, and possess inducible cytochrome P450 enzymatic activities, including CYP 1A2 and CYP 3A4. The exVive 3D Liver has successfully differentiated between structurally related compounds with known toxic and non-toxic profiles in human beings, and the model has also been employed successfully in the detection of metabolites at extended time points in vitro. Importantly, the configuration of the bioprinted liver tissues enables both biochemical and histologic data to be collected so that a customer can investigate compound responses at multiple levels.

The durability and functionality of the 3D liver product enable the assessment of the effects of low dose or repeated dosing regimens across a spectrum of biochemical, molecular, and histologic end points.  All testing will be performed at Organovo’s facility by the Company’s laboratory services tissue experts.

For more information or to discuss specific study requirements, clients can contact us at sales@organovo.com, or visit our website at www.organovo.com.

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company plans to market its first product of a planned portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing prior to the end of 2014, and remains on track to bring this breakthrough technology to customers.  In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the market acceptance of the Company’s products; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed with the SEC on November 7, 2014, as well as our other filings with the SEC. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

(CANF) Near-Term Milestones Timetable for 2014/2015

PETACH TIKVA, Israel, Nov. 18, 2014  — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced several upcoming and near-term milestones on its CF101 and CF102 indications for liver cancer, rheumatoid arthritis, psoriasis, glaucoma and the development of a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

The Company believes that it is on the cusp of reaching several significant milestones in its studies, with respect to CF102 for the treatment liver cancer and CF101 with respect  to the treatment of rheumatoid arthritis, psoriasis and glaucoma. The below near-term key events provide an outlook of Can-Fite’s objectives and potential for increased growth.

Key Milestones for 2014/2015:

CF101

• Q4 2014 – Planning Phase III trials for rheumatoid arthritis following the release of positive Phase II study results.
• Q1 2015 – Announce data for Phase II/III trial for psoriasis with 300 patients for which Can-Fite has already received positive interim data from the first 100 patients .
• Q2/Q3 2015 – Announce data for the Phase II study for glaucoma with 88 patients.

CF102

• Q4 2014 – Patient enrollment has commenced for a Phase II trial in Israel, Europe and the U.S. for the treatment of patients with advanced liver cancer as a second line therapy.

Biomarker

• Q4 2014 – A3AR predictive biomarker blood test kit which will have commercial applications. The commercial kit is designed to be used prior to treatment to help identify an individual patient’s responsiveness to the Company’s drugs, providing more personalized medicine.
• The U.S. Patent and Trademark Office previously issued a patent for the utilization of A3AR as a biomarker to predict patient response to CF101 in autoimmune inflammatory indications.

“We are very excited at the opportunity of potentially receiving further validation on our drug candidates which represents significant steps forward in our commitment to delivering treatments to patients. We hope to see this come to fruition upon conclusion of our psoriasis, liver cancer and glaucoma trials.” stated Can-Fite CEO Dr. Pnina Fishman.

Can-Fite’s leading proprietary compounds, CF101 and CF102, are centered on multi-billion dollar market opportunities. According to GlobalData, the psoriasis drug market is forecasted to grow from $3.6 billion in 2010 to $6.7 billion by 2018, while the rheumatoid arthritis drug market according to independent business information provider visiongain, is predicted to generate revenues of $38.5 billion by 2017. GIA projects that the global liver cancer drugs market will exceed $2 billion by 2015 and GlobalData projects that the glaucoma market to top $3 billion by 2018.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information, please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite’s filings with the SEC and in its periodic filings with the TASE.  In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114

IRTH Communications
Robert Haag
canf@irthcommunications.com
1-866-976-4784

(AMRN) Presentation of Vascepa® MARINE and ANCHOR Analyses At AHA

Analyses Extend Findings on Vascepa Treatment Effects, Including Effects on Top of Statin Therapy

(FOLD) Announces Public Offering of Common Stock

CRANBURY, N.J., Nov. 17, 2014  — Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has commenced a $75 million underwritten public offering of its common stock. J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering. Cowen and Company, LLC and Leerink Partners are acting as lead managers and Janney Montgomery Scott is acting as co-manager for the offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.

The Company expects to use the net proceeds of the offering for investment in the global commercialization infrastructure for migalastat monotherapy for Fabry disease, the continued clinical development of its product candidates and for other general corporate purposes.

The securities described above are being offered by Amicus pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement relating to the offering will also be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 (telephone number: 866-803-9204).

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat) in combination with ERT for Pompe disease.

Forward-Looking Statements

Statements in this press release concerning Amicus’ future expectations, plans and prospects, including, without limitation, statements regarding the proposed public offering, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements due to various risks, uncertainties and important factors, including those set forth in the “Risk Factors” section in the preliminary prospectus supplement relating to the offering and in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission, any of which could cause its actual results to differ from those contained in the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

FOLD–G

CONTACT: Investors/Media:
         Amicus Therapeutics
         Sara Pellegrino
         Director, Investor Relations
         spellegrino@amicusrx.com
         (609) 662-5044

         Media:
         Pure Communications
         Dan Budwick
         dan@purecommunicationsinc.com
         (973) 271-6085

(MSBF) MHC and MSB Financial MHC and MSB Financial

MILLINGTON, N.J., Nov. 17, 2014  — MSB Financial MHC (the “MHC”) and MSB Financial Corp, a federal corporation (the “Company”) (Nasdaq:MSBF), the holding company for Millington Savings Bank (the “Bank”), announced today that their Boards of Directors have unanimously adopted a Plan of Conversion pursuant to which the Company will reorganize into a new stock holding company and will conduct a second-step stock offering of new shares of common stock.

As part of the conversion, the Bank will become a wholly owned subsidiary of a new stock holding company, which will also be named MSB Financial Corp. The shares of common stock of the Company held by persons other than the MHC will be converted into shares of common stock of the new stock holding company pursuant to an exchange ratio designed to preserve the approximate percentage ownership interests of such persons.  The shares of the Company held by the MHC will be cancelled and the amount of the MHC’s ownership interest in the Company will be sold through the second-step stock offering.  In the stock offering, depositors of the Bank, with qualifying deposits as of September 30, 2013 will have first priority to purchase the new shares of common stock.

Michael A. Shriner, President and Chief Executive Officer, stated, “We believe the second-step transaction is an important milestone in the more than 100 year history of the Bank, and it will permit us to raise additional capital and to move forward with our growth and strategic plans. The conversion will also eliminate the operational uncertainties associated with the mutual holding company structure under the Dodd-Frank Act.”

The conversion and offering will have no impact on depositors, borrowers or other customers of the Bank. The transactions contemplated by the Plan of Conversion, are subject to approval by the Company’s stockholders (including approval by a majority of the shares held by persons other than the MHC), the depositors of the Bank and the Board of Governors of the Federal Reserve System.

The Bank’s Board of Directors has also authorized a change of the name of the Bank to “Millington Bank.”  It is expected that the name change will be effective concurrent with the closing of the conversion transaction.

A prospectus or proxy statement/prospectus, as applicable, and other materials containing detailed information relating to the Plan of Conversion, details of the offering, and business and financial information about the Company and new stock holding company will be sent to stockholders of the Company and eligible depositors of the Bank following regulatory approval.

This release is neither an offer to sell nor a solicitation of an offer to buy common stock.  The offer is made only by the prospectus when accompanied by a stock order form.  The shares of common stock of the new holding company are not savings accounts or savings deposits, may lose value and are not insured by the Federal Deposit Insurance Corporation or any other government agency.

Forward-Looking Statements

Certain statements contained herein are “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward looking statements may be identified by reference to a future period or periods, or by the use of forward looking terminology, such as “may,” “will,” “believe,” “expect,” “estimate,” “anticipate,” “continue,” or similar terms or variations on those terms, or the negative of those terms. Forward looking statements are subject to numerous risks and uncertainties,  including, but not limited to: the failure to obtain the approval of the Board of Governors of the Federal Reserve for the proposed conversion and related stock offering, delays in obtaining such approval, or adverse conditions imposed in connection with such approvals; those related to the real estate and economic environment, particularly in the market areas in which the Company operates; fiscal and monetary policies of the U.S. Government; changes in government regulations affecting financial institutions, including regulatory compliance costs and capital requirements; changes in prevailing interest rates; credit risk management; asset-liability management; and other risks described in the Company’s filings with the Securities and Exchange Commission.

The Company wishes to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. The Company wishes to advise readers that the factors listed above could affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake and specifically declines any obligation to publicly release the results of any revisions, which may be made to any forward looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

About MSB Financial Corp.

MSB Financial Corp. is the holding company for Millington Savings Bank, a community financial institution that offers a full range of traditional deposit and lending services, including one-to-four family mortgage loans, home equity loans and lines of credit and consumer loans, including auto loans, personal loans and account loans, and financing for commercial real estate, including multi-family dwellings/apartment buildings, service/retail and mixed-use properties, churches and non-profit properties, medical and dental facilities and other commercial real estate, and residential and commercial construction loans and commercial and industrial loans. Millington Savings Bank currently operates from its main office in Morris County, New Jersey and four branch offices located in Somerset County, New Jersey. MSB Financial Corp.’s principal executive offices are located in Millington Savings Bank’s main office, 1902 Long Hill Road, Millington, New Jersey.

CONTACT:  MSB Financial Corp.
          Michael Shriner, President and CEO
          908-647-4000
          mshriner@millingtonsb.com

(SNSS) Late-Breaking Presentation of Phase 3 VALOR Trial

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2014  — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company’s Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML) will be presented in a late-breaking oral presentation at the 56^th American Society of Hematology Annual Meeting, taking place December 6-9 in San Francisco, California.

“We are very pleased that VALOR, the largest randomized company-sponsored trial ever conducted in relapsed or refractory AML, has been accepted as a late-breaking presentation at ASH,” said Daniel Swisher, Chief Executive Officer of Sunesis. “Despite meaningful progress in other hematologic malignancies, relapsed refractory AML remains a disease where outcomes are unacceptably poor and drug therapy has changed little in the last forty years. We believe the results of VALOR demonstrate a clinically meaningful and important advancement in the treatment of this disease, and we appreciate the opportunity to share the full dataset with the medical community.”

Details of the VALOR presentation and two related AML presentations at the ASH Annual Meeting are as follows:

VALOR Late-Breaking Oral Presentation (LBA-6)

MD Anderson Cancer Center Phase I/II Study Oral Presentation (385)

Prevalence and Incidence of AML (958)

About QINPREZO™ (vosaroxin)

QINPREZO™ (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Preclinical data demonstrate that QINPREZO both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Both the U.S. Food and Drug Administration (FDA) and European Commission have granted orphan drug designation to QINPREZO for the treatment of AML. Additionally, QINPREZO has been granted fast track designation by the FDA for the potential treatment of relapsed or refractory AML in combination with cytarabine. QINPREZO is an investigational drug that has not been approved for use in any jurisdiction.

The trademark name QINPREZO is conditionally accepted by the FDA and the EMA as the proprietary name for the vosaroxin drug product candidate.

About AML

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates there will be approximately 18,860 new cases of AML and approximately 10,460 deaths from AML in the U.S. in 2014. Additionally, it is estimated that the prevalence of AML across major global markets (U.S., France, Germany, Italy, Spain, United Kingdom and Japan) is over 50,000. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.

For additional information on Sunesis, please visit http://www.sunesis.com.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

This press release contains forward-looking statements, including statements related to Sunesis’ preliminary analysis, assessment and conclusions of the results of the VALOR trial, and the efficacy and commercial potential of vosaroxin. It is possible that such results or conclusions may change based on further analysis of the VALOR data. Words such as “will,” “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis’ current expectations. Forward-looking statements involve risks and uncertainties. Sunesis’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis’ preliminary analysis, assessment and conclusions of the results of the VALOR trial set forth in this release may change based on further analysis of such data and the risk that Sunesis’ clinical studies for vosaroxin may not lead to regulatory approval. These and other risk factors are discussed under “Risk Factors” and elsewhere in Sunesis’ Annual Report on Form 10-K for the year ended December 31, 2013, and Sunesis’ other filings with the Securities and Exchange Commission, including Sunesis’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Sunesis’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

CONTACT: Investor and Media Inquiries:
         David Pitts
         Argot Partners
         212-600-1902

         Eric Bjerkholt
         Sunesis Pharmaceuticals, Inc.
         650-266-3717

(VYFC) Signs Definitive Agreement To Acquire Roanoke-Based Valley Financial

HIGH POINT, N.C. and ROANOKE, Va., Nov. 17, 2014 — BNC Bancorp (“BNC,” NASDAQ: BNCN), the holding company for Bank of North Carolina, and Valley Financial Corporation (“Valley,” NASDAQ: VYFC), the holding company for Valley Bank, have entered into a definitive agreement pursuant to which BNC will acquire all of the common stock of Valley in a stock transaction valued at approximately $101.3 million, based on the closing price of BNC common stock on November 14, 2014.

Valley, headquartered in Roanoke, Virginia, operates nine branches in Roanoke and Salem.  As of September 30, 2014, Valley reported approximately $857 million in assets, $607 million in loans, $682 million in deposits and $57 million in tangible common equity.  Upon completion of the transaction, BNC is expected to have approximately $5.0 billion in assets, $3.6 billion in loans, and $4.0 billion in deposits.  The transaction is expected to be immediately accretive to BNC’s fully diluted earnings per share, excluding deal costs.

Under the terms of the agreement, which has been approved by the Boards of Directors of both companies, Valley shareholders will receive a fixed price of $20.50 for each share of Valley common stock, payable in shares of BNC common stock based upon the 20-day volume weighted average price of BNC common stock prior to the closing of the merger, subject to minimum and maximum exchange ratios.  If the VWAP immediately prior to the merger is greater than or equal to $18.50 then each share of Valley common stock shall be converted into 1.1081 shares of BNC common stock (the “Minimum Exchange Ratio”). If the VWAP immediately prior to the merger is less than $14.25, then each share of Valley common stock shall be converted into 1.4386 shares of BNC common stock (the “Maximum Exchange Ratio”). The transaction, which is subject to regulatory approval, the approval of the shareholders of Valley and BNC, and other customary conditions, is expected to close in the second quarter of 2015.

Commenting on the announcement, Rick Callicutt, President and Chief Executive Officer of BNC, said, “We are pleased to announce the combination of BNC and Valley, the leading community bank in the Roanoke market. This partnership will allow us to enter the Commonwealth of Virginia with a sizable presence in the Roanoke MSA and a top 4 deposit market share. We are most excited about Ellis Gutshall and his team joining BNC to continue to expand the most formidable community bank in the Roanoke Valley. Our combined companies will be well positioned for further expansion in Virginia.  The similar culture and core values of Valley and BNC will allow us to accelerate the integration, deepen existing customer relationships, and focus on growth in Southwest Virginia.  The Valley team has built a bank that aligns with our vision of a high performing community bank that creates value for all of its stakeholders while “Delivering More” than our customers expect.”

Ellis Gutshall, President and Chief Executive Officer of Valley, added, “We are pleased to join forces with BNC Bancorp to provide enhanced and long-term value to our customers and communities.  Our combination with BNC, with combined total assets of approximately $5.0 billion, will provide greater capital resources and operational scale that will allow us to grow with the robust Roanoke economy and capture additional market share. In addition, BNC’s track record for creating and growing shareholder value will be a major plus for the Valley shareholder base.”

Womble Carlyle Sandridge & Rice, LLP provided legal counsel to BNC, while Banks Street Partners, LLC served as financial advisor to BNC.  Sandler O’Neill + Partners, LP served as financial advisor to Valley and has rendered a fairness opinion to its Board of Directors in connection with this transaction.  Williams Mullen provided legal counsel to Valley.

INVESTOR PRESENTATION

Further information on the terms of this transaction will be included in a Form 8-K to be filed by each of BNC and Valley with the Securities and Exchange Commission (“SEC”) and will be available at http://www.bncdeliversmore.com/investorpresentation.

ABOUT BNC BANCORP

Headquartered in High Point, NC, BNC Bancorp is the parent company of Bank of North Carolina, a commercial bank with $5.0 billion in assets (following completion of the acquisition of Valley).  Bank of North Carolina provides a complete line of banking and financial services to individuals and businesses through its 48 banking offices in North and South Carolina, which will increase to 60 banking offices, to include Virginia after completion of the pending acquisitions of Harbor Bank Group, Inc. and Valley.  Bank of North Carolina is insured by the FDIC and is an equal housing lender.  BNC Bancorp’s stock is traded and quoted in the NASDAQ Capital Market under the symbol “BNCN.”

ABOUT VALLEY FINANCIAL CORPORATION

Valley Financial Corporation is the holding company for Valley Bank, which opened in 1995 and engages in a general commercial and retail banking business in the Roanoke Valley, emphasizing the needs of small businesses, professional concerns and individuals. Valley Bank currently operates from nine full-service offices. Additionally, Valley Bank operates its wealth management subsidiary, Valley Wealth Management Services, Inc., and its mortgage office in Roanoke. The common stock of Valley Financial Corporation is traded on the NASDAQ Capital Market under the symbol VYFC.

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking information that is intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “may,” “hope,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “continue,” “could,” “future” or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss the future expectations or state other “forward-looking” information about BNC and/or Valley. Such statements involve inherent risks and uncertainties, many of which are difficult to predict and are generally beyond the control of BNC or Valley. Forward-looking statements speak only as of the date they are made and BNC and Valley assume no duty to update such statements. In addition to factors previously disclosed in reports filed by BNC or Valley with the SEC, additional risks and uncertainties may include, but are not limited to: the possibility that any of the anticipated benefits of the proposed merger will not be realized or will not be realized within the expected time period; the risk that integration of Valley’s operations with those of BNC will be materially delayed or will be more costly or difficult than expected; the inability to complete the merger due to the failure of shareholder approval to adopt the merger agreement; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed merger to close for any other reason; the effect of the announcement of the merger on customer relationships and operating results; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; and general competitive, economic, political and market conditions and fluctuations. Additional factors affecting BNC and Valley are discussed in each company’s respective Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Please refer to the SEC’s website at www.sec.gov where you can review those documents.

ADDITIONAL INFORMATION

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval.  In connection with the merger, BNC will file with the SEC a Registration Statement on Form S-4 that will include a Proxy Statement of Valley and a Prospectus of BNC, as well as other relevant documents concerning the proposed transaction. SHAREHOLDERS ARE STRONGLY URGED TO READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED MERGER WHEN IT BECOMES AVAILABLE AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION REGARDING THE PROPOSED MERGER. A free copy of the Proxy Statement/Prospectus, as well as other filings containing information about BNC or Valley, may be obtained after their respective filing at the SEC’s Internet site (http://www.sec.gov). In addition, (i) free copies of documents filed by BNC with the SEC may be obtained on the BNC website at www.bncbancorp.com or by requesting them in writing from Drema Michael, BNC Bancorp, 3980 Premier Drive, Suite 210, High Point, North Carolina 27265, or by telephone at (336) 869-9200; and (ii) free copies of documents filed by Valley with the SEC may be obtained on the Valley website at www.myvalleybank.com or by requesting them in writing from Kimberly Snyder, Valley Financial Corporation, 36 Church Avenue, S.W., P.O. Box 2740, Roanoke, Virginia 24011, or by telephone at (540) 342-2265.

BNC and Valley and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Valley’s shareholders in connection with the proposed merger. Information about the directors and executive officers of BNC and Valley and other persons who may be deemed participants in the solicitation will be included in the Proxy Statement/Prospectus.  Information about BNC’s executive officers and directors can also be found in BNC’s definitive proxy statement in connection with its 2014 Annual Meeting of Shareholders filed with the SEC on April 10, 2014. Information about Valley’s executive officers and directors can also be found in Valley’s definitive proxy statement in connection with its 2014 Annual Meeting of Shareholders filed with the SEC on March 19, 2014. Additional information regarding the interests of those persons and other persons who may be deemed participants in the transaction may be obtained by reading the Proxy Statement/Prospectus regarding the proposed merger when it becomes available. You may obtain free copies of each document as described in the preceding paragraph.

(VSTA) Signs LOI w/ NIMH, NIH-Sponsored Phase 2 Clinical Study of AV-101

(SREV) Appoints Rishi Bajaj to Join Board of Directors

ServiceSource® (NASDAQ:SREV), the global leader in recurring revenue and customer success management, today announced that it has appointed Rishi Bajaj, a Managing Principal and Portfolio Manager of Altai Capital Management, L.P. (“Altai Capital”), to its Board of Directors. Mr. Bajaj has extensive experience in finance and capital markets, and his appointment is expected to bring additional expertise to ServiceSource’s Board as the company continues to execute on its strategy to return the business to growth and profitability. With the addition of Mr. Bajaj, the ServiceSource Board has been increased to nine members.

“We have enjoyed getting to know Rishi since Altai Capital’s first investment in ServiceSource in 2012 and we have valued Altai’s thoughts and insights regarding our business,” said Bruce Dunlevie, lead director of ServiceSource. “We are pleased to bring Rishi’s perspective to the board room as we continue to work diligently to increase shareholder value.”

“ServiceSource is a recognized leader in the growing Recurring Revenue Management industry,” said Mr. Bajaj. “I am excited to work with management and the Board to help restore ServiceSource’s profitability and better deliver and communicate the exceptional value inherent in this company for the benefit of customers and stakeholders.”

Prior to co-founding Altai Capital, Mr. Bajaj was a Senior Analyst at Silver Point Capital, L.P. and a Mergers and Acquisitions and Restructuring Analyst at Gleacher Partners, Inc. Mr. Bajaj holds a Bachelor of Science degree in Economics with concentrations in Finance and Statistics from the Wharton School, University of Pennsylvania.

Altai Capital Management, L.P. is an SEC-registered investment advisor to private investment funds. Altai Capital employs a value-oriented strategy to make investments in various corporate securities and instruments, including equities, bank debt and bonds. Altai beneficially owns approximately 14% of ServiceSource’s outstanding common stock.

About ServiceSource

ServiceSource International, Inc. (NASDAQ: SREV) is the global leader in recurring revenue and customer success management. B2B companies use ServiceSource to drive growth and build long-standing relationships across the customer lifecycle. Through its software and services, ServiceSource delivers higher subscription, maintenance and support revenue, and improved customer retention. Headquartered in San Francisco, ServiceSource® manages over $14.5 billion in revenue for the world’s largest and most respected technology, industrial, healthcare and life sciences, and media and information companies. For more information, go to www.servicesource.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the benefits of ServiceSource offerings, including our cloud platform and applications and, as applicable, our managed services offerings. These forward-looking statements are based on our current assumptions and beliefs, and involve risks and uncertainties that could cause our results to differ materially from those expressed or implied in our forward-looking statements. Those risks and uncertainties include, without limitation, fluctuations in our quarterly results of operations; the risk of material defects or errors in our software offerings or their failure to meet customer expectations; migrating customers to Renew OnDemand and other SaaS offerings and the ability to integrate such offerings with other third-party applications used by our customers; errors in estimates as to the renewal rate improvements and/or service revenue we can generate for our customers; our ability to grow the market for service revenue management; our ability to protect our intellectual property rights; the risk of claims that our offerings infringe the intellectual property rights of others; changes in market conditions that impact our ability to sell the Renew OnDemand or other SaaS solutions and/or generate service revenue on our customers’ behalf; the possibility that our estimates of service revenue opportunity under management and other metrics may prove inaccurate; demand for our offering that falls short of expectations; our ability to keep customer data and other confidential information secure; our ability to adapt our solution to changes in the market or new competition; general political, economic and market conditions and events; and other risks and uncertainties described more fully in our periodic reports and registration statements filed with the Securities and Exchange Commission, which can be obtained online at the Commission’s website at http://www.sec.gov. All forward-looking statements in this press release are based on information currently available to us, and we assume no obligation to update these forward-looking statements.

Connect with ServiceSource:

http://www.facebook.com/ServiceSource

http://twitter.com/servicesource

http://www.linkedin.com/company/servicesource

http://www.youtube.com/user/ServiceSourceMKTG

Trademarks

ServiceSource, Renew OnDemand, Scout and any ServiceSource product or service names or logos above are trademarks of ServiceSource International, Inc. All other trademarks used herein belong to their respective owners.

(UTSI) Announces Company Repurchase Program of Up to $40 Million

HONG KONG, Nov. 14, 2014 — UTStarcom (Nasdaq:UTSI), a global telecommunications infrastructure provider, announced that its Board of Directors has approved a share repurchase program of up to $40 million of its outstanding shares over the next 24 months. The share repurchase program was approved by UTStarcom’s Board of Directors and became effective on November 12, 2014.

During the repurchase program period, the Company will also maintain the flexibility to turn the program to an accelerated repurchase program and/or a cash tender offer. UTStarcom expects to implement this share repurchase program in a manner consistent with market conditions and the interests of the shareholders. The repurchase program does not obligate UTStarcom to make repurchases at any specific time or situation. UTStarcom’s Board of Directors will review the share repurchase program periodically and may authorize adjustment of its terms and size accordingly. In addition, UTStarcom plans to fund any share repurchases made under this program from the Company’s available cash balance. As of September 30, 2014, UTStarcom’s cash and cash equivalents totaled $90.5 million.

Mr. Himanshu Shah, Chairman of UTStarcom’s Board of Directors, stated, “Our commitment to an aggressive share repurchase program reflects the Board’s confidence in the Company and our determination to deliver enhanced value for UTStarcom’s shareholders. We believe that this buy back also represents an effective use of the Company’s cash and we look forward to delivering enhanced value to our shareholders.”

About UTStarcom Holdings Corp.

UTStarcom (Nasdaq:UTSI) is a global telecom infrastructure provider dedicated to developing technology that will serve the rapidly growing demand for bandwidth from cloud-based services, mobile, streaming, and other applications. We work with carriers globally, from Asia to the Americas, to meet this demand through a range of innovative broadband packet optical transport and wireless/fixed-line access products and solutions. The Company’s end-to-end broadband product portfolio, enhanced through in-house Software Defined Networking (SDN)-based orchestration, enables mobile and fixed-line network operators and enterprises worldwide to build highly efficient and resilient future-proof networks for a range of applications, including mobile backhaul, metro aggregation, broadband access and Wi-Fi data offload. Our strategic investments in media operational support service providers expand UTStarcom’s capabilities in the field of next generation video platforms. UTStarcom was founded in 1991, started trading on NASDAQ in 2000, and has operating entities in Hong Kong; Tokyo, Japan; San Jose, USA; Delhi and Bangalore, India; Hangzhou, China. For more information about UTStarcom, please visit http://www.utstar.com.

Forward-Looking Statements

This press release includes forward-looking statements, including statements regarding the Company’s share repurchase program. These statements are forward-looking in nature and subject to risks and uncertainties that may cause actual results to differ materially and adversely from the Company’s current expectations. These include risks and uncertainties related to, among other things, changes in the financial condition and cash position of the Company, changes in the composition of the Company’s management and their effect on the Company, the Company’s ability to realize anticipated results of operational improvements and benefits of the divestiture transaction, the ability to successfully identify and acquire appropriate technologies and businesses for inorganic growth and to integrate such acquisitions, the ability to internally innovate and develop new products, assumptions the Company makes regarding the growth of the market and the success of the Company’s offerings in the market, and the Company’s ability to execute its business plan and manage regulatory matters. The risks and uncertainties also include the risk factors identified in the Company’s latest annual report on Form 20-F and current reports on Form 6-K as filed with the Securities and Exchange Commission. The Company is in a period of strategic transition and the conduct of its business is exposed to additional risks as a result. All forward-looking statements included in this press release are based upon information available to the Company as of the date of this press release, which may change, and the Company assumes no obligation to update any such forward-looking statements.

CONTACT: For investor and media inquiries, please contact:

         Jane Zuo
         UTStarcom Holdings Corp.
         Tel: +852-3750-7632
         Email: jane.zuo@utstar.com

         Daniel DelRe (Hong Kong)
         Tel: +852-3768-4547
         Email: Daniel.DelRe@fticonsulting.com

         Simona Kormanikova (New York)
         +1-212-850-5685
         Email: Simona.Kormanikova@fticonsulting.com

         May Shen (Beijing)
         Tel: +86-10-8591-1951
         Email: May.Shen@fticonsulting.com

(CETV) Refinancing of 2017 Fixed Rate Notes

Transaction Highlights

• Improves debt maturity profile with nearest maturity now at the end of 2017
• Secures attractive pricing on new debt with credit support from Time Warner
• Increases free cash flow through option to pay credit support fees and interest in kind for potential use in reducing the principal amount of its 15% Senior Secured Notes due 2017
• Significantly reduces borrowing costs under existing Revolving Credit Facility

HAMILTON, Bermuda, Nov. 14, 2014  — Central European Media Enterprises Ltd. (“CME” or the “Company”) (Nasdaq:CETV) (Prague Stock Exchange:CETV) today announced that it will redeem all outstanding 9.0% Senior Notes due 2017 (the “2017 Fixed Rate Notes”) issued by its wholly owned subsidiary CET 21 spol. s r.o. (“CET 21”) and that it has entered into a commitment letter with Time Warner Inc. (“Time Warner”) to refinance its 5.0% Senior Secured Convertible Notes due 2015 (the “2015 Convertible Notes”), which mature on November 15, 2015.

CME also announced that it has entered into a EUR 250,800,000 senior unsecured term credit facility agreement dated as of November 14, 2014 (the “2017 Third Party Credit Agreement”) with BNP Paribas, as administrative agent, Time Warner, as guarantor, and the lenders party thereto, and with BNP Paribas Securities Corp. and Crédit Agricole Corporate and Investment Bank acting as joint-lead arrangers and joint bookrunners, to fund the 2017 Fixed Rate Notes redemption.

2017 Refinancing

The 2017 Third Party Credit Agreement will bear cash interest at three-month EURIBOR, fixed at approximately 0.21% pursuant to customary interest rate hedging agreements entered into today, plus a margin between 1.07% and 1.90% (depending on the credit rating of Time Warner) and will mature on November 1, 2017. Additionally, CME will pay Time Warner a guarantee fee equal to 8.50% minus the rate of interest paid to the lenders under the 2017 Third Party Credit Agreement (the “Guarantee Fee Rate”), multiplied by the principal amount of loans outstanding under the 2017 Third Party Credit Agreement at any time, payable semi-annually in cash or in kind at CME’s option, with unpaid amounts accruing interest at the Guarantee Fee Rate, payable in cash or in kind at CME’s option. CME may prepay the loans under the 2017 Third Party Credit Agreement in whole or in part at any time from June 1, 2016 without premium or penalty.

Loan proceeds under the 2017 Third Party Credit Agreement will be applied to redeem and discharge in full the EUR 240,000,000 aggregate principal amount of the 2017 Fixed Rate Notes, including premium. CET 21 issued a notice of redemption on November 14, 2014 and expects the redemption and discharge of the 2017 Fixed Rate Notes to be completed on or about December 14, 2014.

2015 Refinancing Commitment

The 2015 Refinancing Commitment Letter provides that Time Warner will, at its option, either (i) assist CME to arrange a senior unsecured U.S. dollar term credit facility (the “2015 Refinancing Third Party Credit Agreement”) on terms substantially the same as the 2017 Third Party Credit Agreement that will mature on November 1, 2019, that will be guaranteed by Time Warner and certain of its subsidiaries, in consideration of a guarantee fee calculated in the same manner as for the 2017 Third Party Credit Agreement, or (ii) provide CME a senior secured term loan facility (the “2015 Refinancing Time Warner Term Loan Agreement”) on terms substantially similar to CME’s existing term loan agreement with Time Warner, bearing interest in cash or in kind at 8.50% per annum that will mature on November 1, 2019 (in either case in an amount sufficient to repay at maturity the $261.0 million aggregate principal amount of the 2015 Convertible Notes). CME expects to complete the financing and repay the 2015 Convertible Notes immediately prior to their maturity on November 15, 2015. As consideration for providing the commitment, CME will pay Time Warner a commitment fee of approximately $9.1 million, payable by the maturity date of the 2015 Refinancing Third Party Credit Agreement or the 2015 Refinancing Time Warner Term Loan Agreement, as applicable. Unpaid amounts will bear interest at a rate of 8.50% per annum from the date the applicable term loan is first drawn, in cash or in kind, at CME’s option. Upon refinancing the 2015 Convertible Notes, CME’s interest costs and fees under the new facility (including the guarantee fee payable to Time Warner, if the loan is arranged through a bank) will be 8.50% on a per annum basis, with any interest costs or fees owed to Time Warner payable in cash or in kind at CME’s option.

Amendment to Revolving Credit Facility

CME also entered into an amended and restated revolving loan facility credit agreement with Time Warner, as administrative agent, and the lenders party thereto (the “Restated Time Warner Revolving Loan Agreement”) to, among other things, reduce the applicable interest rates for loans made under the facility. Amounts outstanding under the Restated Time Warner Revolving Loan Agreement will bear interest at a rate based on, at CME’s option, the alternate base rate (as defined in the Restated Time Warner Revolving Loan Agreement) plus 8% or the adjusted LIBO rate plus 9%. The remaining terms of the Restated Time Warner Revolving Loan Agreement remain substantially the same as the original revolving loan facility credit agreement dated as of May 2, 2014.

In a joint statement Michael Del Nin and Christoph Mainusch, Co-Chief Executive Officers of CME said: “The transactions we have announced reflect the improved financial position following the turnaround evident in our results and deliver a number of important benefits. First and foremost, they provide the Company with the certainty today that we will be able to refinance our nearest debt maturity, extending the closest debt maturity date to the end of 2017. Second, they reduce the borrowing cost for our existing Revolving Credit Facility. And third, our ability to pay in kind a large portion of the interest and fees on the new debt enhances free cash flow generation that can be used to reduce the principal amount of higher coupon debt. Together, these transactions better position the Company to begin reducing its leverage over time as the turnaround in operations continues, while maintaining our flexibility to refinance the 15% Senior Secured Notes due 2017 at any time.”

CME is a media and entertainment company operating leading businesses in six Central and Eastern European markets with an aggregate population of approximately 50 million people. CME broadcasts a total of 33 television channels in Bulgaria (bTV, bTV Cinema, bTV Comedy, bTV Action, bTV Lady and Ring.bg), Croatia (Nova TV, Doma, Nova World and MiniTV), the Czech Republic (TV Nova, Nova Cinema, Nova Sport, Fanda, Smichov and Telka), Romania (PRO TV, PRO TV International, Acasa, Acasa Gold, PRO Cinema, Sport.ro, MTV Romania, PRO TV Chisinau and Acasa in Moldova), the Slovak Republic (TV Markíza, Doma and Dajto), and Slovenia (POP TV, Kanal A, Brio, Oto and Kino). CME is traded on the NASDAQ Global Select Market and the Prague Stock Exchange under the ticker symbol “CETV”.

Forward-Looking Statements

This press release contains forward-looking statements. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or are otherwise beyond our control and some of which might not even be anticipated. Forward-looking statements reflect our current views with respect to future events and because our business is subject to such risks and uncertainties, actual results, our strategic plan, our financial position, results of operations and cash flows could differ materially from those described in or contemplated by the forward-looking statements.

CONTACT: For further information visit: www.cme.net, or contact:

         Mark Kobal
         Head of Investor Relations
         Central European Media Enterprises
         +420 242 465 576
         mark.kobal@cme.net

(RMGN) Amends Its Senior Credit Facility

Increases Senior Credit Facility to $14 Million; Adds Approximately $2 Million in Net Cash Proceeds

(SPU) Q3 Revenue Up 79% to $34.8 Million, Net Income Increases 45% to $4.7 Million

XI’AN, China, Nov. 14, 2014  — SkyPeople Fruit Juice, Inc. (NasdaqGM: SPU), (“SkyPeople” or “the Company”), a producer of fruit juice concentrates, fruit juice beverages and other fruit-related products, today announced financial results for the third quarter ended September 30, 2014.

Third Quarter 2014 Summary:

• Revenue was $34.8 million, an increase of 79% year-over-year
• Gross profit was $10.2 million, an increase of 41% year-over-year
• Income from operations was $7.2 million, an increase of 57% year-over-year
• Net income was $4.7 million, an increase of 45% year-over-year
• Cash and cash equivalents were $52.7 million as of September 30, 2014

“We are very pleased to report these strong financial results, highlighted by a balanced contribution to revenue among our core products due to the general availability of fresh fruit raw materials during the quarter,” said Mr. Hongke Xue, chief executive officer of SkyPeople. “These quarterly results confirm our strategy for procuring sufficient quantities of fresh fruit by locating our production facilities near fruit growing centers in large fruit producing provinces.

“In terms of our major project initiatives, our project to develop a manufacturing base for kiwi products in Mei County has shown progress with the construction of a kiwi fruit and fruit-related materials trading zone now mostly completed.  Our orange development project in Hubei Province is also making progress with the goal of these two projects to meaningfully expand our processing capabilities.

“SkyPeople now sells its fruit juice beverages to more than 20,000 retail stores in some 20 provinces in China,” said Mr. Xue, and he expects these figures to continue to improve in the quarters ahead.

“China’s rising incomes, we believe, are speeding the transition in consumer tastes towards healthy living, including the increased consumption of high-quality fruit juice beverages. We are therefore well positioned to capitalize on this trend and to continue to capture additional market share,” said Mr. Xue.

Third Quarter 2014 Financial Results

Revenue.  Revenue for the three months ended September 30, 2014 was $34.8 million, an increase of 79% compared to $19.5 million for the same period of 2013. This increase was due to an increase in sales in almost all of our product lines, offset by the decrease of revenue from the other products segment.

Third Quarter 2014 Revenue by Product Segment

Third Quarter 2014 Gross Profit by Product Segment

The company’s gross profit was $10.2 million in Q3 2014, an increase of 41% from $7.2 million for the same period in 2013.  The increase was primarily due to the increase in gross profit generated from apple-related products, concentrated pear juice, fruit juice beverages, fresh fruits and vegetables and other products segments, which was partially offset by a lesser amount of gross profit generated from kiwi-related products..

Operating Expenses. Operating expenses for the third quarter of 2014 were $3.0 million, or 9% of sales, as compared to $2.6 million, or 13% of sales for Q3 2013. General and administrative expenses decreased 19% to $1.3 million for Q3 2014 as compared to $1.6 million for the same period of 2013, but selling expenses increased 63% in Q3 2014 to $1.6 million as compared to $1.0 million for the same period of 2013, mainly due to an increase in payroll and related expenses necessary to handle the company’s increased sales.

Income from Operations. Income from operations was $7.2 million for the third quarter of 2014, an increase of 57% as compared to $4.6 million for the same period of 2013.

Net Income and Earnings Per Share. Net income for the third quarter of 2014 was $4.7 million, an increase of 45% as compared to $3.3 million for the same period of 2013, primarily due to the 41% increase in gross profit.  Earnings per share attributable to SkyPeople Fruit Juice for the third quarter of 2014 was $0.17 as compared to $0.11 for the same period of 2013.

Nine Months 2014 Financial Results

Revenue for the nine months ended September 30, 2014 was $58.6 million, an increase of 21% compared to $48.4 million for the same period of 2013. Gross profit was $18.4 million, an increase of 1% compared to $18.2 million for the same period of 2013. Gross margin for the nine months ended September 30, 2014 was 31% compared to 38% in the same period of 2013. Operating expenses for the first nine months of 2014 were $7.4 million, or 13% of sales, as compared to $7.2 million, or 15% of sales for the same period of 2013. General and administrative expenses were $3.5 million, a decrease of 17% as compared to $4.2 million for the same period of 2013. Selling expenses were $3.9 million, an increase of 31% as compared to $3.0 million for the same period of 2013. Income from operations for the nine months ended September 30, 2014 was $10.99 million, a decrease of less than 1% as compared to $11.03 million for the same period of 2013. Net income attributable to SkyPeople Fruit Juice for the first nine months ended September 30, 2014 was $5.1 million, or $0.19 per share, compared to $7.5 million, or $0.28 per share, for the same period of 2013.

Third Quarter 2014 Financial Condition

As of September 30, 2014, the company had $52.7 million in cash, cash equivalents and restricted cash, compared to $74.1 million as of fiscal year end 2013. The Company’s restricted cash of $18.8 million consisted of cash equivalents used as collateral to secure short-term notes payable. SkyPeople’s working capital as of September 30, 2014 was $31.3 million, a decrease in working capital of $71.9 million as of December 31, 2013.  As of September 30, 2014, the Company had total liabilities of $99.5 million including $44.9 million in short-term bank loans and bank notes payable, an $8.0 million long-term loan to a related party and $20.2 million in capital lease obligations. As of September 30, 2014, shareholders’ equity attributable to SkyPeople was $177.1 million as compared to $173.5 million as of fiscal year-end 2013.

Conference Call

The Company will hold a conference call on Monday, November 17, 2014 at 9:00 am Eastern Time to discuss its financial results for the third quarter ended September 30, 2014. The Company’s Chairman, Mr. Yongke Xue, and Chief Financial Officer, Mr. Xin Ma, will host the call.

To attend the live conference call, please dial in at least 10 minutes before the call to ensure timely participation.  Please use the dial-in information below.

To access the replay, please dial 1-877-660-6853 within the United States or 1-201-612-7415 when dialing internationally. The pass code for the replay is 13595110 and it will be available from November 17, 2014 at 12:00 pm through November 24, 2014.

About SkyPeople Fruit Juice, Inc.

SkyPeople Fruit Juice, Inc., a Florida company, through its wholly-owned subsidiary Pacific Industry Holding Group Co., Ltd. (“Pacific”), a Vanuatu company, and SkyPeople Juice International Holding (HK) Ltd., a company organized under the laws of Hong Kong Special Administrative Region of the People’s Republic of China and a wholly owned subsidiary of Pacific, holds 99.78% ownership interest in SkyPeople Juice Group Co., Ltd. (“SkyPeople (China)”). SkyPeople (China), together with its operating subsidiaries in China, is engaged in the production and sales of fruit juice concentrates, fruit beverages, and other fruit related products in the PRC and overseas markets. Its fruit juice concentrates are sold to domestic customers and exported directly or via distributors. Fruit juice concentrates are used as a basic ingredient component in the food industry. Its brands, “Hedetang” and “SkyPeople,” which are registered trademarks in the PRC, are positioned as high quality, healthy and nutritious end-use juice beverages. For more information, please visit http://www.skypeoplefruitjuice.com.

Safe Harbor Statement

Certain of the statements made in this press release are “forward-looking statements” within the meaning and protections of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “point to,” “project,” “could,” “intend,” “target” and other similar words and expressions of the future.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2013 and otherwise in our SEC reports and filings, including the final prospectus for our offering. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC’s Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.

(NETE) Announces Third Quarter 2014 Results

Significant Reduction of Liabilities and Positive Cash Flow from Operations Sets the Company on the Path to Growth

MIAMI, Nov. 13, 2014 — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a technology-driven group specializing in mobile payments and value-added transactional services in emerging countries and in the United States, today announces its financial results for the third quarter ended September 30, 2014. The results reflect ongoing financial strength as Net Element continues to generate positive cash flow from operations, turning from losses for the same period a year ago.

Conference Call

Net Element will host a conference call to discuss the financial and business highlights.

It is recommended that participants dial in approximately 10 minutes prior to the start of the 4:30PM Eastern call. A webcast replay will be available following the call on the investor relations site http://investor.netelement.com/events.cfm.

For the three and nine months ended September 30, 2014, Net Element’s financial results from continuing operations, excluding one-time charges, have significantly improved. The Company’s ongoing strategy is to grow its business organically and through acquisition while providing custom technology solutions and managing costs in an increasingly competitive environment.

Third Quarter 2014 Highlights:

• Announced $11 million financing from Alfa-Bank. The financing will allow Net Element to accelerate its growth efforts in Russia;
• SeeThruEquity issued company update on Net Element, increasing its price target guidance to $5.17 per share;
• Finalized debt exchange transaction with Crede CG III, Ltd., strengthening Net Element’s balance sheet;
• Announced availability of Apple Pay to merchants, offering mobile payments so more customers can pay when, where and how they want;
• Eliminated more than $15 million of debt from its balance sheet. The financial transaction settles most of the Company’s debt obligations and strengthens its fundamentals;
• Attended SeeThruEquity Fall Microcap Investor conference in New York;
• Leadership appointed to Electronic Transactions Association (ETA) committees. The appointment demonstrates Net Element’s commitment to the payments industry and expands Company’s visibility in industry organization;
• SeeThruEquity initiated research coverage on Net Element with initial target price of $3.47 per share;
• Appointed financial services industry veteran William Healy to the Net Element board of directors;
• Announced $10 million financing from RBL Capital Group, LLC. The financing will allow Net Element to accelerate its growth initiatives.

“We are pleased with our third–quarter performance, which includes significant debt reduction and narrowed quarterly loss. Pivoting from a stronger balance sheet, our activities and improvements have set the pace for continued growth and demonstrate our commitment to increasing company value,” says Company Chief Executive Officer Oleg Firer. “We’re proud to present these results to our shareholders and look forward to maintaining this momentum heading into 2015. The perpetual evolution of cashless transactions and mobile commerce offers exciting opportunities for Net Element, and we look forward to advancing our potential in this market.”

Third Quarter 2014 Operating Results:

Net Element’s total debt was $3,315,000 at September 30, 2014, versus total debt of $21,071,624 at December 31, 2013, representing a reduction of $17,756,624. This reduction in debt was in the Company’s transaction processing and mobile payments businesses. Net Element has significantly and continually reduced its debt and related interest expense.  On September 15, 2014, the Company completed a debt exchange program with Crede CG III, Ltd., which eliminated both the Capital Sources of New York, LLC ($2.3 million) and Georgia Notes 18, LLC ($13.5 million) debt obligations.  Additionally, Net Element’s factoring line at Alfa-Bank was $2,939 at September 30, 2014 as compared to $8,478,810 at December 31, 2013.  This is due to timing of the renewal of this line of credit and lower current volume of Russian mobile payment.

In an effort to present a more comparative period on period analysis, Net Element has adjusted net loss to remove the effects of non-recurring expenses from discontinued operations, non-cash share based compensation, goodwill impairment, debt extinguishment and debt restructuring.  Net Element has also adjusted its mobile payment gross margin to analyze trends excluding penalties charged and recovered.  Adjusted gross margin, adjusted loss from continuing operations and adjusted earnings per share are non-GAAP measures that are detailed later in this press release in the section “Reconciliation of Non-GAAP Financial Measures”.

The adjusted loss from continuing operations for the three months ended September 30, 2014 was $2,225,498 or a loss of $0.05 per share as compared to an adjusted loss from continuing operations of $3,366,475 or a loss of $0.11 per share for the three months ended September 30, 2013.

The adjusted loss from continuing operations for the third quarter ended September 30, 2014, was $2,225,498, or a loss of $0.05 per share, as compared to an adjusted loss from continuing operations of $3,366,475, or a loss of $0.11 per share, for the third quarter of 2013.  The Company attributes the adjusted loss from the third quarter primarily to interest expense ($790,490), depreciation and amortization ($684,503) and general and administrative expenses (primarily salaries and professional fees)($750,505).  Going forward interest expense and depreciation and amortization will be considerably lower as a majority of the Company’s debt was paid-off September 18, 2014 and amortization will be lower as each quarter the Company reaches full amortization on additional capitalized portfolios.

Third quarter 2014 net revenues were $6,026,961, as compared to $6,520,788 for the year ago quarter. The decrease in net revenues is substantially due to reduced Russian mobile payment processing revenues as Net Element restructured this business with new management and its own proprietary billing system to position it for future growth.  Russian mobile payment revenues were $461,328 for the third quarter of 2014 and $338,295 for the second quarter ended June 30, 2014.  The Company expects to record quarterly growth in its Russian mobile payment processing business with revenues for the second quarter 2014 being the lowest level of revenues. Third-quarter transaction processing revenues in the United States increased by $55,975.

Cost of revenues for the third quarter of 2014 was $4,717,855 as compared to $4,646,245 for the third quarter of 2013. The increase in cost of revenues of $71,610 is primarily a result of a higher mix of U.S. transaction processing business for the third quarter of 2014 as compared to the comparable quarter of 2013 where Net Element had more mobile payment processing business with a lower cost of sales.

Gross Margin for the third quarter of 2014 was $1,309,106 (22%) as compared to $1,874,543 (29%) for the third quarter of 2013. The reason for the decrease in the margin percentage was a change in business mix and portfolio make-up. Net Element’s business mix had more transaction processing business in the third quarter of 2014 versus the same period in 2013. The Company’s portfolio make-up has changed as its older, higher margin portfolios have run-off and been replaced with new portfolio at lower competitive margins. The following table sets forth the Company’s gross margin mix.  It should be noted that penalty charges and abatements have distorted the mobile payments margin percentages in the table below. Excluding penalties, gross margin for mobile payments was 95% for the third quarter of 2014 as compared to 86% for the comparable quarter of 2013.

General and administrative expenses, excluding non-cash compensation expense, were $1,910,315 for the third quarter ended September 30, 2014, as compared to $2,853,528 for the same period of 2013.  This was primarily due to reductions of $454,972 in salaries and benefits; $267,419 in professional fees; $106,032 in travel expense; and $53,588 in rent expense.  The reduction in salaries and benefits is due to net headcount reductions; professional fees and travel are lower due to reorganization in the third quarter of 2013 after the Company’s successful merger transaction, and consequently higher professional fees and travel, with Unified Payments in April of 2013.  Rent expense is $53,588 lower since Net Element was able to use the office space acquired in the merger.

Interest expense for the third quarter of 2014 amounted to $790,490 versus $973,256 of interest expense for the third quarter of 2013.  Interest for the three months ended September 30, 2014, consisted of $436,005 interest on the Georgia Notes 18, LLC loan (loan was paid off September 2014); $57,500 interest from the Company’s Capital Sources of New York, LLC loan (loan was paid off in September 2014); $63,647 from the Company’s RBL Capital Group, LLC loan; $229,956 from the MBF Merchant Capital, LLC (debt restructured loan that was paid off July 2014); and $3,381 due to the Alfa-Bank credit facility.

Total interest expense for the three months ended September 30, 2013, amounted to $973,256, of which $448,519 was due to Georgia Notes 18, LLC; $178,312 was for the factoring line TOT Money had with Alfa-Bank; and the remaining $346,425 balance was interest due to the outstanding RBL Capital Group, LLC, MBF Merchant Capital, LLC and Capital Sources of New York, LLC notes.

Year to date 2014 Operating Results:

For the nine months ended September 30, 2014, Net Element’s adjusted loss from continuing operations was $3,770,945, or a loss of $0.08 per share, as compared to an adjusted loss from continuing operations of $15,406,137, or a loss of $0.51 per share, for the nine months ended September 30, 2013.

Net Element acquired Unified Payments in April 2013 and in September of 2013 divested the Company’s non-core entertainment assets, becoming a company focused on mobile payment processing, transaction processing services and payment technologies.  As such, it is difficult to draw comparisons between Net Element’s 2013 year-to-date results and 2014 year-to-date results.

Net revenues were $15,782,475 for the first nine months of 2014, as compared to $12,966,538 for the comparable nine months of 2013. The increase in net revenues is primarily due to nine months of activity in 2014 as compared to five and one-half months of activity in 2013 for TOT Payments processing fees. This increase was offset by $1,561,151 of revenue from Net Element’s former First Data Portfolio for the nine months ended September 30, 2013, which did not repeat during the nine months ended September 30, 2014.  Revenue replacement and growth was achieved by organic growth of the Company’s current portfolios and the purchase of certain portfolios for the nine months ended September 30, 2014.

Cost of revenues for the nine months ended September 30, 2014, was $11,591,435 as compared to $9,036,826 for the same period of 2013. The year-over-year increase in cost of revenues of $2,554,609 is primarily a result of nine months of operations of TOT Payments in 2014 versus five and a half months of operations of TOT Payments in 2013. The increase in cost of sales was offset by a $653,217 recovery of mobile operator penalties during the past nine months.

Gross Margin for the nine months ended September 30, 2014, was $4,191,040 (27%) as compared to $3,929,712 (30%) for the nine months ended September 30, 2013. The reason for the decrease in the overall margin percentage was due to the decrease in mobile payments business for the nine months ended September 30, 2014, as compared to the nine months ended September 30, 2013.  Additionally, new portfolios have lower more competitive margin than older portfolio. The following table sets forth Net Element’s gross margin mix.  Note that penalties have distorted the mobile payments margin percentage in the table below.  Normalizing mobile payment margins by taking out penalties provides an adjusted gross margin of 93% for the nine months ended September 30, 2014, compared to 93% for the nine months ended September 30, 2013.

Operating expenses, excluding non-cash compensation expense and non-cash goodwill impairment totaled $7,442,681 for the nine months ended September 30, 2014, as compared to $17,153,987 for the comparable nine months of 2013.

Net Element’s recovery from loan loss provision was $1,302,554 for the nine months ended September 30, 2014, as compared to an expense provision of $6,736,302 of expense for the comparable nine months of 2013, representing a decrease of $8,038,856. The Company recorded a net recovery in provision for loan losses of $1,302,554 for the nine months ended September 30, 2014, which consisted of a favorable adjustment to the bad debt allowance of $1,640,111 in the second quarter that was associated with Russian operations, offset by loss provision for net ACH rejects of $337,557 in U.S. credit card processing business. Net Element reported a $6,736,302 loss provision for the nine months ended September 30, 2013, primarily due to unrecoverable advances from Russian aggregators.

Professional fees were $2,102,719 for the nine months ended September 30, 2014, as compared to $3,348,821 for the same nine months of 2013, representing a decrease of $1,246,102 primarily from reductions in general legal expenses ($870,194), Audit expenses ($673,461), and SEC legal compliance expenses ($234,839).  These decreases were offset by increases in consulting of $494,933 and tax compliance of $37,459.  General legal costs were lower as the Company did not have the merger or divesture in 2014 that occurred in 2013.  Auditing fees were lower for the same reason and because the Company moved to a new audit firm with lower rates.

Salaries, benefits, taxes and contractor payments were $2,335,774 for the nine months ended September 30, 2014, as compared to $3,250,901 for the nine months ended September 30, 2013, representing a decrease of ($915,127).  The Company reduced salaries and benefits by $477,036 in Netlabs (Engineering), $311,450 in Russia, $203,644 in Music1 (business divested), and $114,993 from headcount reductions in TOT Group.

Travel expenses for the first nine months of 2014, were $218,194 as compared to $646,260 of travel expenses for the nine months ended September 30, 2013.  There was extensive travel during the first six months of 2013 as Net Element’s senior management was not located in Miami and the Company was integrating its merger with Unified Payments.

Net Element’s cash provided by operating activities was $2,959,201 for the nine months ended September 30, 2014 compared to cash used in operating activities of ($6,366,221) for the nine months ended September 30, 2013. Positive operating cash flow for the nine months ended September 30, 2014 was primarily due to the reduction of accounts and note receivable offset primarily by losses and lower accrued expenses.

Reconciliation of Non-GAAP Financial Measures and Regulation G Disclosure

To supplement its consolidated financial statements presented in accordance with United Stated generally accepted accounting principles (“GAAP”), the Company provides additional measures of its operating results by disclosing its adjusted loss on a continuing operations basis and adjusted gross margin excluding penalties.  Adjusted loss on a continue operations basis is calculated as loss from continuing operations excluding discontinued operations, non-cash share based compensation, goodwill impairment, debt extinguishment and debt restructuring costs.  Net Element discloses this amount on an aggregate and per share basis.  Additionally, the Company is disclosing its mobile payments gross margin adjusted for penalties charged and recovered to analyze the trend of gross margin without penalties. These measures meet the definition of non-GAAP financial measures. The Company believes that application of these non-GAAP financial measures is appropriate to enhance the understanding of its historical performance through use of a metric that seeks to normalize period to period earnings and gross margin.

This press release contains non-GAAP financial measures within the meaning of Regulation G promulgated by the Securities and Exchange Commission.  Pursuant to Regulation G, a reconciliation of these non-GAAP financial measures with the comparable financial measures calculated in accordance with GAAP for the three and nine months ended September 30, 2014 and 2013 follows:

About Net Element (NASDAQ: NETE)
Net Element (NASDAQ: NETE) is a global technology-driven group specializing in mobile payments and value-added transactional services. The Company owns and operates a global mobile payments and transaction processing provider, TOT Group. TOT Group companies include Unified Payments, recognized by Inc. Magazine as the #1 Fastest Growing Private Company in America in 2012, Aptito, a next generation cloud-based point of sale payments platform, and TOT Money, which has a leading position in Russia and has been ranked as the #1 SMS content provider by Beeline, Russia’s second largest telecommunications operator. Together with its subsidiaries, Net Element enables ecommerce and adds value to mobile commerce environments. Its global development centers and high-level business relationships in the United States, Russia and Commonwealth of Independent States strategically position the Company for continued growth. The Company has U.S. headquarters in Miami and headquarters in Moscow. More information is available at www.netelement.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, whether Net Element or its business continues to grow and whether the financing secured by Net Element will be adequate to meet the Company’s objectives.  All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element ‘s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element ‘s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element ‘s ability to successfully expand in existing markets and enter new markets; (iv) Net Element ‘s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element ‘s business; (viii) changes in government licensing and regulation that may adversely affect Net Element ‘s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element ‘s business; (x) Net Element ‘s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk that the U.S. government may decide to impose sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K and the subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

(SDPI) to Present at the 2014 Southwest IDEAS Investor Conference

VERNAL, Utah, Nov. 13, 2014 — Superior Drilling Products, Inc. (NYSE MKT:SDPI), a provider of drilling products for the oil, natural gas and mining services industries, announced today that Troy Meier, Chairman and Chief Executive Officer, and Chris Cashion, Chief Financial Officer, will present at the 2014 Southwest IDEAS Investor Conference in Dallas, TX at 1:50 p.m. Central Time on Thursday, November 20, 2014.

A link to the webcast, along with presentation materials, will be available on the Company’s website: www.sdpi.com.

About Superior Drilling Products, Inc.

SDPI is an innovative, cutting-edge drilling tool technology company. The Company manufactures, repairs, sells and rents drilling tools.   SDPI is a manufacturer and refurbisher of PDC (polycrystalline diamond compact) drill bits for a leading oil field services company. In addition, SDPI manufactures and markets drill string tools, including the patented Drill-N-Ream™ well bore conditioning tool, for the oil, natural gas and mining services industries. SDPI operates a state-of-the-art drill tool machining facility manufacturing for its customer’s custom products and solutions for the drilling industry. The Company’s strategy is to leverage is technological expertise in drill tool technology and innovative, precision machining to broaden its drill tool technology offerings for rent or sale, while establishing an effective sales and logistics infrastructure through which it can provide proprietary tools to exploration and production companies and drill rig operators. It also plans to grow its manufacturing operations by providing its oil field services customers with design, prototype development and manufacturing of their proprietary technologies.

Additional information about the Company can be found at its website: www.sdpi.com.

CONTACT: Investor Relations:
         Deborah K. Pawlowski / Garett K. Gough
         Kei Advisors LLC
         (716) 843-3908 / (716) 846-1352
         dpawlowski@keiadvisors.com / ggough@keiadvisors.com

(BBRY) Announces New Partnerships and Broad Enterprise Portfolio

BlackBerry expands enterprise solutions, raising the bar on security, productivity, communication and collaboration

Media Contact:
BlackBerry Media Relations
(519) 888-7465 x77273
mediarelations@BlackBerry.com

Investor Contact:
BlackBerry Investor Relations
(519) 888-7465
investor_relations@BlackBerry.com

(RSTI) Strong Q4 FY2014 Results

PLYMOUTH, Mich. and HAMBURG, Germany, Nov. 13, 2014 — ROFIN-SINAR Technologies Inc. (NASDAQ: RSTI), one of the world’s leading developers and manufacturers of high-performance laser beam sources, laser-based system solutions and components, today announced results for its fourth fiscal quarter and twelve months ended September 30, 2014.

FINANCIAL REVIEW

– Fourth Quarter –

Net sales totaled $146.1 million for the fourth quarter ended September 30, 2014, slightly lower than in the fourth quarter of fiscal year 2013. Gross profit totaled $54.6 million, or 37% of net sales, compared to $50.2 million, or 34% of net sales, in the same period last fiscal year. RSTI net income amounted to $12.0 million, or 8% of net sales, compared to $9.8 million, or 7% of net sales, in the comparable quarter last fiscal year. The diluted earnings per share was $0.43 for the quarter based upon 28.1 million weighted-average common shares outstanding, compared to the diluted earnings per share of $0.35 based upon 28.4 million weighted-average common shares outstanding for the same period last fiscal year.

SG&A expenses in the amount of $27.1 million represented 19% of net sales and increased by $3.0 million, including one-time expenses of approximately $1.2 million, primarily associated with the expansion and modernization of production facilities, compared to last fiscal year’s fourth quarter. Net R&D expenses increased by $1.5 million to $11.5 million and represented 8% of net sales.

Sales of laser products for macro applications increased by 7% to $57.4 million and accounted for 39% of total sales. Sales of lasers for marking and micro applications decreased by 6% to $69.4 million and represented 48% of total sales. Sales of components decreased by 4% to $19.3 million and represented 13% of total sales.

On a geographical basis, revenues in North America decreased year-over-year by 7%, to $28.2 million and by 9% in Europe to $65.8 million, whereas net sales in Asia increased by 16% to $52.1 million.

– Twelve Months –

For the twelve months ended September 30, 2014, net sales totaled $530.1 million, a decrease of $30.0 million, or 5%, when compared to the prior fiscal year. The fluctuation of the US dollar, mainly against the Euro, resulted in an increase in net sales of $8.6 million for the twelve-month period. Gross profit for the period was $188.9 million and $7.6 million lower than in fiscal year 2013. RSTI net income for the fiscal year ended September 30, 2014, totaled $25.2 million. The diluted earnings per share was $0.89 based upon 28.2 million weighted-average common shares outstanding.

Net sales of lasers for macro applications decreased by $5.0 million, or 2%, to $209.6 million and net sales of lasers for marking and micro applications decreased by $22.5 million to $250.2 million. Sales of components decreased $2.5 million, or 3%, to $70.3 million compared to fiscal year 2013.

On a geographical basis, net sales in North America in the twelve months period decreased by 11% year-over-year and totaled $101.9 million (2013: $114.9 million). In Europe, net sales increased by 3% to $256.6 million (2013: $250.3 million) and in Asia, net sales decreased by 12% to $171.6 million (2013: $194.9 million).

– Order Backlog –

Order entry increased by 14% to $141.3 million for the quarter and by 4% to $553.4 million for the fiscal year compared to the corresponding periods in fiscal year 2013. The backlog, mainly for laser products, amounted to $141.3 million as of September 30, 2014. The book-to-bill ratio for the quarter was 0.97.

– Other Developments: Share Buyback –

During fiscal year 2014, the Company purchased approximately 0.3 million shares of common stock under the buyback program, announced in February 2014, for a total amount of $6.2 million.

– Outlook –

For the first quarter ending December 31, 2014, taking into account the anticipated impact of the average exchange rate, the Company expects sales to be in the range of $127 million to $132 million and earnings per share to be in the range of $0.28 to $0.30. At the mid-point of the guidance range, the first quarter outlook represents year-over-year growth of 7% in sales and 262% in earnings per share.

For the fiscal year ending September 30, 2015, taking into account the anticipated impact of the average exchange rate, the Company expects sales to range between $550 million and $570 million and earnings per share to be $1.60 at the mid-point of the sales range. This represents year-over-year growth of 6% in sales at the mid-point of the sales guidance range, and 80% in earnings per share. The Company confirmed its goal to achieve gross profit margin of 40% by the fourth quarter of fiscal year 2015. The improvement in results compared to the prior fiscal year will be a direct result of growth in sales of the Company’s next-generation products, including fiber lasers, and improved profitability from cost reduction measures and production economies of scale.

The Company’s first quarter and fiscal year 2015 guidance takes into account the expected unfavorable impact of the average exchange rate resulting from the recent strengthening of the US dollar, to the extent it continues. The majority of any such impact affects the sales level, with net income being affected to a lesser degree due to natural hedging.

Actual results may differ from this forecast and are subject to the safe harbor statement discussed in more detail below.

With almost 40 years of experience, ROFIN-SINAR Technologies is a leading developer, designer and manufacturer of lasers and laser-based system solutions for industrial material processing applications. The Company focuses on developing key innovative technologies and advanced production methods for a wide variety of industrial applications based on a broad scope of technologies. The product portfolio ranges from single laser-beam sources to highly complex systems, covering all of the key laser technologies such as CO₂ lasers, fiber, solid-state and diode lasers, and the entire power spectrum, from single-digit watts up to multi-kilowatts, as well as a comprehensive spectrum of wavelengths or pulse durations and an extensive range of laser components. ROFIN-SINAR Technologies has its operational headquarters in Plymouth, Michigan, and Hamburg, Germany and maintains production facilities in the US, Germany, UK, Sweden, Finland, Switzerland, Singapore, and China. ROFIN currently has more than 49,000 laser units installed worldwide and serves more than 4,000 customers. The Company’s shares trade on the NASDAQ Global Select Market under the symbol RSTI and are listed in Germany in the “Prime Standard” segment of the Frankfurt Stock Exchange under ISIN US7750431022. ROFIN is part of the Standard & Poor’s SmallCap 600 Index and the Russell 2000 Index. Additional information is available on ROFIN-SINAR’s home page: www.rofin.com.

A conference call is scheduled for 11:00 AM Eastern Time, today, Thursday, November 13, 2014. This call is also being broadcast live over the internet in listen-only mode. The recording will be available on the Company’s home page for approximately 90 days. For a live webcast, please go to www.rofin.com at least 10 minutes prior to the call in order to download and install any necessary software. For more information, please contact Briget Ampudia, Taylor Rafferty, New York at +1-212-889-4350 or Miles Chapman, Taylor Rafferty, London at +44 (0) 207 614 2916.

The full text of the press release and further information including comprehensive financial data is available online at www.rofin.com.

“Safe Harbor” Statement Under the Private Securities Litigation Reform Act

Certain information in this press release that relates to future plans, events or performance, including statements such as “For the first quarter ending December 31, 2014, taking into account the anticipated impact of the average exchange rate, the Company expects sales to be in the range of $127 million to $132 million and earnings per share to be in the range of $0.28 to $0.30. At the mid-point of the guidance range, the first quarter outlook represents year-over-year growth of 7% in sales and 262% in earnings per share.” or “For the fiscal year ending September 30, 2015, taking into account the anticipated impact of the average exchange rate, the Company expects sales to range between $550 million and $570 million and earnings per share to be $1.60 at the mid-point of the sales range. This represents year-over-year growth of 6% in sales at the mid-point of the sales guidance range, and 80% in earnings per share. The Company confirmed its goal to achieve gross profit margin of 40% by the fourth quarter of fiscal year 2015. The improvement in results compared to the prior fiscal year will be a direct result of growth in sales of the Company’s next-generation products, including fiber lasers, and improved profitability from cost reduction measures and production economies of scale.” or “The majority of any such impact affects the sales level, with net income being affected to a lesser degree due to natural hedging.” is forward-looking and is subject to important risks and uncertainties that could cause actual results to differ. Actual results could differ materially based on numerous factors, including currency risk, competition, risk relating to sales growth in CO₂, diode, and solid-state lasers, cyclicality, conflicting patents and other intellectual property rights of fourth parties, potential infringement claims and future capital requirements, as well as other factors set forth in our annual report on Form 10-K. These forward-looking statements represent the Company’s best judgment as of the date of this release based in part on preliminary information and certain assumptions which management believes to be reasonable. The Company disclaims any obligation to update these forward-looking statements.

(VBLT) to Present Interim Phase 2 Data From VB-111 in Recurrent Glioblastoma

— Interim Data Suggest Improved Overall Survival in Patients Treated With VB-111 in Combination With Bevacizumab (Avastin®) —

TEL AVIV, Israel, Nov. 13, 2014 — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases, today announced positive preliminary results from its ongoing Phase 2 trial of VB-111 in patients with recurrent glioblastoma (rGBM). Improved overall survival was suggestive in patients with rGBM who received VB-111 as a standalone drug and who, upon further progression, were treated with VB-111 in combination with bevacizumab (Avastin®) compared to patients treated with bevacizumab alone upon further progression. These study results will be presented at the 19^th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) on November 14, 2014, at 4:30 pm ET, in Americana 3 at the Loews Hotel in Miami, Florida.

“These early clinical data with VB-111 in patients with recurrent GBM, are exciting and demonstrate the potential of the compound’s novel mechanism of action and innovative gene therapy approach,” said principal investigator, Andrew Brenner, MD, PhD, Clinical Investigator with the Cancer Therapy and Research Center at the University of Texas Health Science Center San Antonio. “The survival benefit trend seen in patients who continued on a combination regimen with VB-111 is promising, underscores the need for novel approaches to this debilitating disease, and highlights the potential for this drug to make a difference for our patients.”

“We are pleased by these interim results and are excited to see increased survival in patients on VB-111,” said Dror Harats, MD, Chief Executive Officer of VBL Therapeutics. “These preliminary results are particularly encouraging because, in this trial both longer exposure to VB-111 and combining VB-111 and bevacizumab led to an increase in median overall survival compared to treatment with bevacizumab alone, without safety or tolerability concerns.  We look forward to advancing VB-111 into a pivotal Phase 3 clinical trial in 2015.”

The interim Phase 2 data for VB-111 were presented for 46 patients with rGBM treated with VB-111; upon further progression, 23 of them were treated with VB-111 in combination with bevacizumab, and 23 received bevacizumab alone. VB-111 in combination with bevacizumab demonstrated a numerically improved median overall survival of 504 days, compared to 235 days in patients on VB-111 followed by bevacizumab alone. Tumor response data, available for 15 of the patients who received VB–111 in combination with bevacizumab, showed stable disease or better in 12 patients (80%), reduction of at least 25% in RANO score in nine patients (60%) and partial response, defined by at least 50% reduction in tumor mass, in 3 patients (20%). The Company believes that this decrease in tumor mass and the subsequent increase in overall survival resulted from either increased exposure to VB-111 and/or a synergistic effect of VB-111 combined with bevacizumab, and support the design of VBL’s pivotal Phase 3 study, set to begin in the first half of 2015 under a special protocol assessment agreement granted by the FDA.

In this study, VB-111 was safe and well-tolerated both as a monotherapy and in combination with bevacizumab. Most adverse events observed in the study were low-grade flu-like symptoms, including fever and chills, which occurred on the day of treatment at approximately six hours after infusion, and were transient and controlled with anti-fever medications.

This Phase 1/2 trial is a multi-center, two stage, dose-escalation study designed to determine the safety, tolerability and efficacy of VB-111 in patients with rGBM. In the first phase of the study, patients were treated with VB-111 alone. Upon disease progression, defined as a worsening of the patient’s cancer with an increase of at least 25% in the overall mass of measurable tumors, the appearance of new tumors, the worsening of non-measurable tumors since the beginning of treatment, a need for increased dose of corticosteroids, or clinical deterioration, patients received either bevacizumab alone or bevacizumab in combination with VB-111.

About VB-111:

VB-111 is a novel, intravenously-administered, anti-angiogenic agent that utilizes VBL’s proprietary Vascular Targeting System (VTS™) to target endothelial cells in the tumor vasculature for cancer therapy. VB-111 contains a non-replicating adenovector, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene to angiogenic tumor blood vessels, leading to their apoptosis. VB-111 is the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial.

VB-111 completed a Phase 1/2 “all comers” clinical trial, which demonstrated multiple cases of objective tumor response and disease control and excellent safety and tolerability. VB-111 has Fast Track Designation for recurrent glioblastoma in the US, and orphan drug status for glioblastoma in both the US and EU. VB-111 has also been advanced into tumor specific, repeat-dose trials in thyroid and ovarian cancer.

About VBL:

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics’ clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body’s natural physiologic and genetic regulatory elements. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the pivotal Phase 3 trial for VB-111 in rGBM in the first half of 2015, under a special protocol assessment agreement granted by the FDA. VBL Therapeutics’ lead product candidate from its anti-inflammatory program, VB-201, is an oral small molecule currently being evaluated in Phase 2 clinical trials for psoriasis and for ulcerative colitis, with top-line results expected in the first quarter of 2015.

Forward-Looking Statements:

This press release contains forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Paul Cox
         Stern Investor Relations, Inc.
         (212) 362-1200, paul@sternir.com

(FUEL) Ranked 15th Fastest Growing Company in North America on Deloitte’s Fast 500™

Rocket Fuel (NASDAQ:FUEL), a leading provider of artificial intelligence (AI) advertising and marketing solutions for global agencies and brands, today announced it ranked 15th on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rocket Fuel grew 10,113 percent during the period between fiscal year 2009 to 2013.

As highlighted earlier this week in its Q3 2014 earnings report, the company posted record quarterly revenue results. In 2014, Rocket Fuel fortified its competitive advantage with the acquisition of [x+1] to bring a fully stacked Data Management Platform (DMP) and Demand Side Platform (DSP) solution to the advertising market.

“We’re honored to once again top Deloitte’s list of the fastest growing companies,” said George John, Rocket Fuel CEO. “This achievement demonstrates our increasing engagement with both existing and new advertisers and brands to help them optimize their digital campaigns and achieve real results. It’s an honor shared with the entire Rocket Fuel team, as it reflects our collective determination to transform the ad industry and grow our company with passion and purpose.”

Rocket Fuel previously ranked #1 as a Technology Fast 500™ award winner for 2013.

About Deloitte’s 2014 Technology Fast 500™

Technology Fast 500, conducted by Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences, and clean technology companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2009 to 2013.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years and be headquartered within North America.

About Rocket Fuel

Rocket Fuel delivers a leading programmatic media-buying platform at Big Data scale that harnesses the power of artificial intelligence (AI) to improve marketing ROI in digital media across web, mobile, video, and social channels. Rocket Fuel powers digital advertising and marketing programs globally for customers in North America, Europe, and APAC. Customers trust Rocket Fuel’s Advertising That Learns® platform to achieve brand and direct-response objectives in diverse industries from luxury cars to financial services to retail. Rocket Fuel currently operates in more than 20 offices worldwide and trades on the NASDAQ Global Select Market under the ticker symbol “FUEL.” For more information, please visit http://www.rocketfuel.com or call 1-888-717-8873.

Rocket Fuel
Kenya Hayes, 650-481-6178
pr@rocketfuel.com

(IMDZ) to Present at Jefferies 2014 Global Healthcare Conference

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 13, 2014 — Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer of Immune Design, will present at the Jefferies 2014 Global Healthcare Conference in London on November 19, 2014 at 11:20 a.m. GMT/3:20 a.m. PST. A live audio webcast and archive of the presentation will be available on the company website at http://ir.immunedesign.com/events.cfm.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design’s three on-going immuno-oncology clinical programs are the product of its two synergistic discovery platforms: ZVex^TM and GLAAS^TM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

CONTACT: Media Contact
         Julie Rathbun
         Rathbun Communications
         julie@rathbuncomm.com
         206-769-9219

         Investor Contact
         Robert H. Uhl
         Westwicke Partners
         robert.uhl@westwicke.com
         858-356-5932

(ISSC) FAA Awards STC for B737 NextGen Flight Deck & FMS

Innovative Solutions & Support, Inc.(IS&S) (NASDAQ: ISSC) announced today that it received Federal Aviation Administration (FAA) Supplemental Type Certification (STC) for its Flight Management System (FMS) for Boeing 737 Classic aircraft. As a result, IS&S now offers the most advanced Boeing 737-300/-400/-500 NextGen retrofit, including Required Navigational Performance/Radius to Fix (RNP/RF), Required Time of Arrival (RTA), Localizer Performance with Vertical guidance (LPV) and Wide Area Augmentation System / Global Positioning System (WAAS/GPS) capabilities. The IS&S cockpit upgrade opens a major new aircraft retrofit market worldwide, providing legacy air transport aircraft with navigational capability and performance equivalent to that of the newest production aircraft.

This latest certification is the culmination of a multi-year program to upgrade (2) 737-400 aircraft to full CNS/ATM compliance standards in which IS&S served as the systems integrator. This program included installation of new transponders, cockpit printers, ACARS and SATCOM systems. Relocation of the center console facilitated installation of this new equipment.

The IS&S B737 Classic cockpit upgrade is the first Air Transport retrofit to integrate RNP/RF, LPV and WAAS/GPS approaches supporting a worldwide navigational database, greatly increasing the utility of these aircraft and firmly establishing IS&S as a leader in this market. The RNP and WAAS/GPS capabilities will enable aircraft to fly shorter flight paths and optimum idle-thrust descents, thereby reducing fuel consumption, carbon emissions, and noise levels. LPV capability significantly improves access, with thousands of airports now benefitting from published WAAS LPV procedures.

The IS&S flight deck upgrade replaces legacy CRT and Flight Management avionics, leverages recently developed advanced display and computing technology, and provides the flexibility for functional evolution as NextGen requirements evolve. The IS&S upgrade package includes an advanced flight management system with global navigational database capability, primary & navigational flight displays, and a WAAS/GPS system, and seamlessly integrates DataComm and ADS-B capabilities.

The IS&S NextGen cockpit upgrade package provides further operational benefits, including increased operational flexibility and reliability, improved dispatch and on time arrival availability and simplified maintenance. In addition the system enhances safety through improved situational awareness and reduced crew workload.

The IS&S cockpit upgrade package is easily integrated with third party avionics systems, including the Mode S transponder, the ACARS system, SATCOM, and the cockpit printer. The MCDU acts as the crew interface for these systems through ARINC 739 AOC pages. The Flat Panel Display System installation was specifically designed to minimize aircraft down time due to rewiring. To convert from an EFIS airplane, no wiring modifications are required in the electronics bay, where shelf removal dramatically increases avionics modification complexity – the IS&S FMS Line Replaceable Units (LRUs) are plug-in replacements for the legacy FMS LRUs. Including installation of dual GPS antennas and receivers, the upgrade package installation can be completed in less than five days.

The FMS complements the IS&S Cockpit/IP® display and instrument systems that have been installed on nearly 300 air transport aircraft to-date. The Cockpit/IP® employs IS&S’s open architecture flat panel display system that allows operators to upgrade their aircraft to a glass flight deck while leaving third party avionics installed in the aircraft. The flight management system supports satellite-based operations, which result in improved efficiencies, related to RNAV, RNP, and LPV procedures.

About Innovative Solutions & Support, Inc.

Headquartered in Exton, Pa., Innovative Solutions & Support, Inc. (www.innovative-ss.com) is a systems integrator that designs and manufactures flight guidance and cockpit display systems for Original Equipment Manufacturers (OEM’s) and retrofit applications. The company supplies integrated Flight Management Systems (FMS) and advanced GPS receivers for precision low carbon footprint navigation. IS&S supplies Flight Management solutions to the commercial air transport market, the military aviation market for C-130, L-100 and the business aviation market for the Eclipse E500 and E550 aircraft.

Certain matters contained herein that are not descriptions of historical facts are “forward-looking” (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those discussed in filings made by the Company with the Securities and Exchange Commission. Many of the factors that will determine the Company’s future results are beyond the ability of management to control or predict. Readers should not place undue reliance on forward-looking statements, which reflects management’s views only as of the date hereof. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141112006410/en/

Innovative Solutions & Support, Inc.
Jason Zywalewski, +1-610-646-9800 ext 609
jzywalewski@innovative-ss.com

(ERII) Changes Investor and Analyst Day to Monday, December 8 in New York City

SAN LEANDRO, Calif., Nov. 12, 2014 — Energy Recovery Inc. (Nasdaq:ERII), the leader in capturing reusable energy from industrial fluid flows and pressure cycles, has announced a new date and location for its Investor and Analyst Day, now being held on Monday, December 8, 9:30am-2:30pm, at the Mandarin Oriental Hotel in New York City. The event will unveil a new, disruptive technology for an as-yet-unnamed major industry, and guide investors and analysts through a dynamic and new business strategy for 2015 and beyond.

Led by CEO Tom Rooney, this will be the first analyst-focused event Energy Recovery has hosted in more than five years. The forum will allow the management team to provide investors and potential shareholders critical information to help them make informed decisions about the Company.

In addition to announcing a disruptive new technology, the Company will provide significant detail on its new growth markets, including oil and gas and chemical processing, and will share details on new products, value propositions, total addressable markets and a comprehensive business strategy that will position Energy Recovery as the leading innovator in the field, tapping pressure energy to drive uptime and profitability in oil and gas, chemicals and water. The day will also include an update on the state of the desalination market.

Interested Parties

Individuals interested in attending can contact Adam Prior of The Equity Group Inc. at aprior@equityny.com or by calling (212) 836-9606.

About Energy Recovery Inc.

Energy Recovery (Nasdaq:ERII) develops award-winning innovations that make industrial processes more productive, more profitable and environmentally cleaner. Our solutions tap into pressure energy from fluid flows to drive uptime throughout industrial processes. By recycling otherwise lost pressure energy, we are able to make systems more efficient and reduce overall maintenance costs, with solutions customized to adapt to all conditions. Working in oil & gas, chemical and water industries, more than 15,000 solutions worldwide save clients over $1.4 Billion (USD). Headquartered in the San Francisco Bay Area, Energy Recovery has offices in Madrid, Shanghai, and Dubai. Learn more at www.energyrecovery.com

CONTACT: Adam Prior
         The Equity Group Inc.
         aprior@equityny.com
         (212) 836-9606

(MITK) Optimizes Mobile Web Photo Capture of Driver’s Licenses and Other IDs

New Browser-Based Image Capture to Drive Revenue by Speeding Consumer Enrollment and Improving Forms Completion

SAN DIEGO, Nov. 12, 2014  — Mitek (Nasdaq:MITK) (www.miteksystems.com), the leading innovator of mobile imaging for financial transactions and identification, today announced it will be optimizing photo capture of driver’s licenses and other IDs through mobile browsers. The addition of this capability to the Company’s awarding winning Mobile Photo Account Opening™ Suite will help financial brands drive revenue by speeding mobile enrollment process and improving forms completion rates for new accounts.

According to comScore, mobile devices accounted for 55% of Internet usage in the United States in January 2014. For this reason, digital strategists and marketers need to create a superior mobile web user experience to win new customers and drive new revenue. By adding the ability to evoke the camera via a browser to Mitek’s Mobile Photo Account Opening, marketers will be able to achieve higher conversions from targeted digital marketing campaigns as well as capture those shopping online for new financial services using mobile devices.

Mitek estimates an increase in form completion rates of 30% – 50% for new bank accounts, credit card applications and more. The data accuracy of photo pre-fill will significantly improve the ability of back-end systems to apply business rules for real-time decisioning increasing the number of new accounts opened and applications approved.

“Our customers asked us for an acquisition tool to help them drive new revenue from mobile web,” said James B. DeBello, president & CEO of Mitek. “We are responding to their needs by embedding advanced computer vision technology into mobile browsers to create a powerful tool that will help them achieve their goals.”

Mitek’s Mobile Photo Account Opening for Mobile Web is easy to implement. The mobile web team embeds the Mitek Mobile Web Capture SDK into their website which provides a turnkey image capture and enhancement capability while ensuring no images are saved to the device. Images are securely sent to and returned from Mitek’s mobile imaging server through simple web services calls. This approach allows financial services organizations to quickly configure to meet their needs and minimizes the IT resources required to deploy.

Mobile Photo Account Opening for Mobile Web will be generally available in Q2 2015. The server side can be deployed in Mitek Cloud or on-premise.

About Mitek

Headquartered in San Diego, CA, Mitek (Nasdaq:MITK) is the leading innovator of mobile imaging for financial transactions and identification. Mitek’s patented mobile photo technology automatically captures images of financial and personal documents and then extracts relevant data. This enables consumers to use the Camera as a Keyboard™ to reduce friction for mobile check deposit, account opening, bill payment, insurance quoting, and many other use cases. This innovative technology is licensed by more than 3,000 organizations and used by tens of millions of consumers enabling increased customer acquisition, retention and operational efficiency. www.miteksystems.com MITK-G

Follow us on LinkedIn: http://www.linkedin.com/company/mitek-systems-inc.
Follow us on Twitter: @miteksystems
See us on YouTube: http://www.youtube.com/miteksystems
Read our latest blog post: http://www.miteksystems.com/blog

CONTACT: Media Contacts:

         Ann Reichert
         Senior Director of Marketing
         pr@miteksystems.com

         Katherine Verducci
         MIX Public Relations
         pr@mix-pr.com

(ESCA) Announces Executive Management Change

EVANSVILLE, Ind., Nov. 12, 2014  — Escalade, Incorporated (NASDAQ: ESCA) announced today that it will be consolidating its finance and accounting department effective at the end of its fiscal year on December 27, 2014. At that time, Stephen R. Wawrin will assume the additional duties as Escalade’s Vice President, Finance and Chief Financial Officer. Since 2008, Mr. Wawrin has served as Vice President –Finance and Administration for Escalade’s Sporting Goods business. He joined Escalade in 2005, and previously served as Corporate Controller for Escalade, Inc. Mr. Wawrin will succeed Deborah J. Meinert, Escalade’s current Vice President Finance, Chief Financial Officer, and Secretary, who will be leaving Escalade at that time.

The decision to restructure Escalade’s finance and accounting department results from Escalade’s strategic decision to focus on its Sporting Goods business. With the divestiture of its Information Security and Print Finishing business, Escalade’s executive management and board of directors determined that certain functions could be consolidated. This management change does not impact or in any way relate to the financial statements or reporting of Escalade or its subsidiaries.

Robert J. Keller, Escalade’s President and Chief Executive Officer, said, “We thank Deborah for her service over the last seven years. Deborah has made many contributions to the success of Escalade, and we wish her the best in the future.”  Mr. Keller continued, “Stephen is an integral part of our Sporting Goods team and we look forward to his continued leadership as we seek to grow our Sporting Goods business.  We anticipate a smooth transition in the Company’s business and financial operations as Stephen assumes his expanded role.”

Escalade is a leading manufacturer and marketer of sporting goods products sold worldwide. To obtain more information on the Company and its products, visit our website at: www.EscaladeInc.com or contact Robert J. Keller, President and CEO at 812/467-1288.

FORWARD LOOKING STATEMENTS

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. These risks and uncertainties include, but are not limited to,  risks relating to changes to our management team, the impact of competitive products and pricing, product demand and market acceptance, new product development, Escalade’s ability to achieve its business objectives, especially with respect to its Sporting Goods business on which it has chosen to focus, Escalade’s ability to successfully achieve the anticipated results of strategic transactions, including the integration of the operations of acquired assets and businesses and the divestiture of its Information Security and Print Finishing Segment, the continuation and development of key customer and supplier relationships, Escalade’s ability to control costs, general economic conditions, fluctuations in operating results, changes in foreign currency exchange rates, changes in the securities markets, Escalade’s ability to obtain financing and to maintain compliance with the terms of such financing, and other risks detailed from time to time in Escalade’s filings with the Securities and Exchange Commission. Copies of these filings are available from the Company and on the SEC’s website at www.sec.gov.  Escalade’s future financial performance could differ materially from the expectations of management contained herein.  Escalade undertakes no obligation to release revisions to these forward-looking statements after the date of this press release.

(BIOC) Launches Lung Cancer Offering

Blood-Based Liquid Biopsy Testing Launched for NSCLC Indications

SAN DIEGO, Nov. 12, 2014  — Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and Circulating Tumor Cells (CTCs), today announced the launch of its lung cancer liquid biopsy testing that will be performed at the Company’s CLIA-certified and CAP-accredited laboratory.

By launching blood-based biomarker testing for non-small cell lung cancer (NSCLC), along with the previously commercialized breast cancer offering, Biocept is providing options for health care providers and researchers when a tumor biopsy is not available, is unsafe to perform or when additional information is desired. For patients with recurrent or newly diagnosed metastatic lung cancer, accurate identification of genomic biomarker information is a key piece of information that clinicians need when making treatment decisions. A challenge for physicians has been availability of tissue from the surgical biopsy that is required to perform the biomarker testing. This limitation occurs as a result of tumor location or health of the patient. According to a recent study¹, when lung biopsies are attempted, there is a 19.3% risk of complication such as a collapsed lung or an infection. Managing these complications quadruples the cost of care. In comparison, the cost of a simple blood draw is nominal, and poses little risk for patients, and the Company believes it has the potential to simultaneously save cost and improve outcomes for the health care system.

The Company’s first CLIA-validated assay for lung cancer will be testing for ALK fusions on CTCs captured in Biocept’s patented device. ALK is incorporated into the testing guidelines utilized by oncologists when making treatment decisions in NSCLC patients. ALK positive patients now have targeted treatment options with two key drugs that have been approved by the FDA: the first is Pfizer’s Xalkori (Crizotinib) and the second is Novartis’s Zykadia (ceritinib), and others are in development.

“The evaluation of biomarker status is the standard-of-care in determining the course of therapy for patients with lung cancer,” said Michael Nall, President and CEO of Biocept. “We are excited to be able to help physicians by providing actionable genomic information for lung cancer patients with a simple blood test.”

“A liquid biopsy, or blood based genomic test, has the advantage of being far less invasive than a surgical biopsy, therefore being appropriate for diagnostic and importantly, monitoring purposes. This gives physicians insight into the molecular status of the patient in real time so that therapeutic changes can be made for better patient outcomes,” says Lyle Arnold, SVP and Chief Scientific Officer of Biocept.

The Company currently plans to offer additional biomarkers for lung cancer that physicians use when making treatment decisions before the end of the year and during 2015, including EGFR mutations, Ros1 fusions, KRAS mutations, and EGFR and MET amplification. EGFR mutation status, like ALK, is a biomarker included in guidelines that oncologists follow to determine the best treatment plan for a patient. Patients who have EGFR mutations are eligible for Tyrosine Kinase Inhibitors such as Tarceva^R from Genentech or Iressa^R from AstraZeneca. In addition, the Company is validating important resistance markers for these targeted therapies that they expect to be used most often when physicians are monitoring patients.

Biocept expects that some of these biomarkers will be performed on CTCs while others will be performed on circulating cell free DNA, which, if successful, has the potential to make Biocept one of the first to offer genomic analysis both on intact cells and plasma.

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics company focused on providing information on patients’ tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA). A standard blood sample is utilized to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BR^TM test for breast cancer and OncoCEE-LU^TM for non-small cell lung cancer and plans to introduce CLIA validated tests for colorectal, prostate and other solid tumors based on its proprietary technology platforms over the coming months.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to cost savings, improvement of outcomes, our impact on diagnostic strategies and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the Securities and Exchange Commission, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

¹Lokhandwala T, Dann R, Johnson M, et al. Costs of the Diagnostic Workup for Lung Cancer – A Medicare Claims Analysis. Presented at: 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology; October 30-November 1, 2014; Chicago, Illinois. Presentation Number: 103.

CONTACT: Investor Contact:
         The Ruth Group
         David Burke
         (646) 536-7009
         dburke@theruthgroup.com

         Media Contact:
         The Ruth Group
         Calvin Allen
         (646) 536-7002
         callen@theruthgroup.com